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Background: Orthodontic tooth movement (OTM) requires mechanical stimuli to 
remodel the periodontal ligament and alveolar bone. During OTM, an inflammatory-like 
response is mediated by various signalling molecules. Two important cytokines involved 
in this response are interleukin-17 (IL-17) and interleukin-6 (IL-6). 
 
Aim: To determine whether the addition of IL-17 and/or IL-6 affects the expression of 
genes associated with osteogenesis. 
 
Methods: Cultures of human calvarial osteoblasts (hCO) (N=1) and human periodontal 
ligament cells (hPDLCs) (N=4) were grown alone or together (co-culture) in the presence 
of 0–75 ng/mL IL-17 and/or IL-6 for 72 hrs. The effect of osteogenic triple supplement 
(TS) was also investigated. Cell viability was monitored with PrestoBlueTM. Levels of 
osteogenic gene expression were determined by qPCR assays. ANOVA and Tukey’s 
post-hoc tests were employed for statistical analysis. 
 
Results: The addition of IL-17 and/or IL-6 had no significant effect on cell viability over 
72 hrs. The addition of TS to hCO baseline mono-cultures resulted in significantly 
increased OPG and ALP mRNA expression compared to negative control (+3.8-fold; 
p=0.020 and +25-fold; p=0.034, respectively). RANK expression increased in response 
to IL-17 in a dose-dependent manner (p=0.003). hPDLCs gene expression were 
unaffected by the addition of IL-6, but showed increased ALP mRNA expression in 
response to IL-17 (4-fold; p=0.042). In co-culture with TS, the addition of IL-17 and  
IL-6 increased hCO RANK expression (+5.8-fold; p = 0.004). hCO ALP expression 
decreased in the presence of IL-17, IL-6, and IL-17 with IL-6 (-148-fold; p=0.001, 2-
fold; p=0.002 and -413-fold; p=0.001 respectively). When compared to monocultures, 
hPDLC RANK mRNA expression was greater for untreated cells (+390-fold), and in the 
presence of IL-17 (+33-fold) and IL-6 (+9888-fold) in co-culture at 48 hrs. 
 
Conclusion: The addition of IL-6 and IL-17 decreases OPG and ALP expression and 
increases RANK in hCOs. This effect is amplified in the presence of hPDLCs, and may 
play a role in stimulation of bone remodelling associated with OTM.  
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Thesis Outline  
This study focuses on the development of a co-culture system of human periodontal 
ligament cells (hPDLC) and human calvarial osteoblasts (hCO) and the dose and time-
dependent effect of interleukin-6 (IL-6) and interleukin-17 (IL-17). It is divided into the 
following four main chapters that are organised as follows:  
 
Chapter 1 - Review of the literature  
An overall discussion of orthodontic tooth movement and the importance of the 
periodontal ligament (PDL) following application of orthodontic force is presented. A 
review of the role of cytokines and cellular communication is also discussed. In 
addition, the influence of key osteogenic genes on bone remodelling and the potential 
for drugs to influence OTM is presented. Laboratory procedures, significance of 
research, aims and objectives of this present study are presented. 
 
Chapter 2 - Core Methods and materials 
The methodological details of this study are presented in the second chapter. Aspects of 
study design, patient recruitment, cell culture and establishment of a co-culture system 
are covered. In addition, cell viability measurements, RNA extraction and purification 
and gene expression analysis is covered. 
 
Chapter 3 – Patient selection, establishment of explant cultures, measurement of 
cell viability and gene expression analysis  
Patient demographics and the establishment of explant cultures are presented. Findings 
from cell viability assays and gene expression analysis is presented  
The dose and time-dependent response of hCOs and hPDLCs to IL-17 and/or IL-6 in 
mono- and co-culture was investigated.  
 
Chapter 4 – Discussion  
A general overview of the results with comparison to current literature. The 






Chapter 5 - Conclusion and Future Research Directions  
The fifth and final chapter of this work highlights the study’s conclusions and the 
exciting avenues that could be investigated in the future. 
 
Chapter 6 – References  
Chapter 7 – Appendices   
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1.1 Orthodontic tooth movement  
 
The ability to move teeth from one point to another in order to correct tooth misalignment 
is a vital part of orthodontic treatment (1). In the modern day era, requests for orthodontic 
treatment have continued to increase due to an increase in demand for better aesthetics 
(2). A clinician’s understanding of the underlying concept of tooth movement allows for 
potentially decreasing overall treatment time, thus improving patient satisfaction (3). 
Development of innovative mechanical orthodontic appliances for tooth movement are 
numerous, however injury to the periodontium or prolonged treatment time can result in 
some cases. Research into the effects of the application of force and subsequent tooth 
movement is well established, however the cellular biology underlying these movements 
is not well understood (3). A greater understanding of bone remodelling pathways will 
help clinicians in the design and utilisation of orthodontic devices resulting in safer and 
potentially more accelerated tooth movement. 
 
Orthodontic treatment duration is of vast importance to both clinicians and patients and 
influenced by many factors. These factors include patient compliance, type of 
malocclusion, impacted teeth, root size and number. However, the main factor 
controlling the rate of orthodontic tooth movement (OTM) is the biological response of 
the periodontal tissues, especially the rate at which bone is resorbed. At the University 
of Otago, the average orthodontic treatment time was identified as 20.7 months. This is 
comparable to international university settings with an average treatment time of 20 
months and 18 visits (4). As a longer treatment time is associated with increased root 
resorption, increased enamel demineralisation, periodontal disease, decreased 
compliance and patient satisfaction, it is beneficial to minimise overall treatment time. 
The biological mediators IL-17 and IL-6 are known to influence bone remodelling. These 
cytokines require further investigation to determine if their presence, or addition of, to 
gingival crevicular fluid could influence OTM and thus treatment times.  Understanding 
how these mediators and cells work in isolation as well as together will create a better 
foundation for our knowledge of OTM. 
 
The periodontal ligament (PDL) plays a key role in maintaining homeostasis of the 
surrounding alveolar bone during physiological, iatrogenic and therapeutic tooth 
18 
 
movement (5, 6). During orthodontic treatment, facilitation of OTM involves the use of 
mechanical stimuli to remodel the PDL and surrounding alveolar bone. OTM is the result 
of a biologic response to interference in the physiologic equilibrium by an externally 
applied force (7). This force results in sites of cellular compression and tension. The PDL 
is vital in absorbing and distributing these forces to the surrounding tissues (8). This 
remodelling of the periodontal tissues is essential in order to effectively move teeth 
orthodontically. Optimal orthodontic force is described as the force required to move 
teeth into the desired position as efficiently as possible, while minimising patient 
discomfort and damage to the periodontal tissues (9). Light forces are often preferred for 
OTM as they induce the desired bone resorption while avoiding hyalinisation and 
undermining resorption. However, it is important to recognise that even light orthodontic 
forces result in some trauma to the surrounding tissues and that the applied force is not 
evenly distributed over the PDL (10, 11). The tissue strain induced by orthodontic force 
produces local alterations in the PDL including changes in vascularity and synthesis and 
release of various neurotransmitters, cytokines and growth factors. A baseline knowledge 
of the biological basis of tooth movement has been established, detailing reactions to 
orthodontic forces at a molecular, cellular and tissue level (7). Despite the advances of 
research in this field, a complete understanding is still lacking.  
 
An explanation of the cellular and molecular biology of tooth movement has been 
proposed by various theories. One widespread theory is the “pressure-tension theory” 
which describes the underlying mechanisms for tooth movement and outlines that the 
tooth being moved has surrounding sites of both tension and compression. An 
inflammatory-like process is initiated on the pressure or compression surface (12). 
Osteoclast activity then results in resorption of alveolar bone on the compression surface. 
Conversely, on the tension surface, bone apposition is stimulated by osteoblastic activity 
(13) (Figure 1.1). This theory is supported through past research involving animal models, 
such as beagle dogs. Animal model studies have indicated that 24 hours after orthodontic 
force application, the remodelling process has already started at the pressure and tension 
surfaces of the tooth (12, 13). These studies provided a good understanding of tooth 
movement. Further in vitro studies will begin to unravel the specific biological 





The tooth, surrounding Periodontal ligament with periodontal ligament cells (in blue), 
osteoblasts (in orange) and osteoclast cells (in green) and bone are drawn. The arrow 
indicates the direction of force. A: Orthodontic force is applied. B: Periodontal ligament 
fibres are stretched at the tension / apposition site and compressed at the site of 
compression/ resorption. C: After prolonged application of force, osteoblasts are 
involved in formation of bone at the sites of tension and osteoclasts are involved with 
resorbing the bone at the sites of pressure / resorption. Adapted from Henneman et al., 
(2008) (14). 
 
The pressure-tension theory has been widely accepted, however, recent studies suggest 
that the process of remodelling of alveolar bone is more complex (15). The evidence to 
support the complexity of alveolar bone remodelling is based on in vitro and animal 
model studies, as we are unable to assess histology in human studies (13). This 
complexity is thought to be due to the PDL being anisotropic (15, 16). This means that 
the physical properties of the PDL have different values when measured in different 
directions (17). The PDL has also been shown to respond non-linearly to orthodontic 
force application (15). The evidence, derived from finite model analysis, suggests that 
the loading of the periodontium cannot simply be explained by the terms of ‘compression’ 
and ‘tension’ along the direction of force (15). Models continue to be developed and 
utilised to investigate OTM as orthodontics undergoes a paradigm shift from a focus on 
the mechanics to the biology of tooth movement. With advancements in molecular 
biology and cell culture techniques, provision of an increased perception into the cellular 
mechanisms of OTM will be possible. This could lead to identification of reliable 
biomarkers, that with greater comprehension of the cellular basis of OTM, could be used 
to improve clinical diagnosis and outcomes.  
Figure 1.1: Diagram indicating the processes occurring at the pressure (resorptive) 
and tension (apposition) sites of a tooth following the application of mechanical 
force with orthodontic treatment. 
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During the process of force distribution, the current evidence suggests that mechanically 
induced remodelling of the surrounding tissue and alveolar bone is mediated by a 
complex feedback mechanism (8). This involves the synthesis of cytokines including 
interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-17 (IL-17) and receptor activator 
of nuclear factor κB ligand (RANKL) by human osteoblast (hO) and fibroblast (including 
PDL) cell lineages (18). PDLCs are fibroblast-like cells which are characterised by 
collagen production but also possess some osteoblastic features. These cells, along with 
hOs, regulate the expression of transcription factors, enzymes, growth factors, cytokines 
and structural molecules in an autocrine/paracrine manner determining various cells 
function, including differentiation and proliferation (19). Throughout OTM, expression 
levels of IL-17 and IL-6 are increased in areas of higher force (8, 20, 21). The risk of root 
resorption increases when the level of applied orthodontic force exceeds the limit of 
which the periodontal ligament can withstand (20). Post-orthodontics, 1-5% of teeth 
show evidence of severe root resorption, however there is limited understanding of the 
mechanisms involved (22, 23). A possible link between IL-6 and an increased risk of 
root resorption has been identified, but the underlying mechanism is yet to be determined 
(21, 24). Due to the involvement of IL-6 in the JAK/STAT pathway, it is possible that 
this pathway is involved in root resorption, but more research is required to confirm this 
hypothesis (24). 
 
It is reasonable to expect periodontal, osteoclast and osteoblast cells to communicate 
throughout OTM and thus alter their activity following their interaction. Cellular 
response can also be influenced by direct cell-cell contact. This contact can be via 
integrins and cell adhesion molecules. Developing an in vitro model in which the cells 
vital to OTM, namely hO and periodontal ligament cells (hPDLC), can interact would 
provide a more realistic model for the environment present in the PDL. This model would 
provide a suitable environment for investigating the effects of IL-6 and IL-17 on hPDLC 





1.2 The use of biomodulators to control orthodontic tooth movement  
 
A clinician’s ability to control tooth movement for greater efficiency and ideal treatment 
outcomes is of utmost importance in orthodontic practice. Different malocclusions 
present challenges for clinicians in terms of planning the avoidance of unwanted tooth 
movement i.e. anchorage control (Figure 1.2). In situations of high anchorage demands, 
when specific control of tooth movement is necessary, a clinician may reinforce 
anchorage by encouraging the use of headgear or skeletal anchorage in order to prevent 
certain teeth from moving. However, if compliance is required and not adhered to, then 















The potential for use of biomodulators in orthodontics to enhance or inhibit recruitment, 
differentiation or activation of cells, such as hPDLC and hO, could result in acceleration 
or reduction of OTM. The potential use of OPG to increase orthodontic anchorage is a 
very promising field, and could rule out the need for headgear or mini-screws to prevent 
movement of teeth. A key regulator of osteoclastogenesis and bone turnover activity is 
the RANKL-osteoprotegerin (OPG) axis (Figure 1.3). Osteoclasts have a RANKL 
receptor which binds to RANK on the cell surface of osteoblasts. RANKL binding leads 
to upregulation of osteoclastic activity, an increase in osteoclast differentiation and a 
decrease in apoptosis (Figure 1.4). Osteoclast activity decreases if OPG binds to RANKL 
on the hO surface. It acts as a decoy, preventing binding of the hO to the osteoclast and 
(A) Class I 
occlusion  
(B) Class I 
malocclusion  
(C) Class II 
malocclusion  
(D) Class III 
malocclusion  
Figure 1.2: Differential tooth movement required in different malocclusions. 
Position of upper and lower teeth in relation to each other in an ideal class I 
occlusion and malocclusion. (A) Class I occlusion, (B) Class I malocclusion, (C) 
Class II malocclusion, (D) Class III malocclusion. Increased anchorage demands are 
demonstrated by the red dots, these areas are where limited tooth movement is 
required in order to correct the malocclusion. Teeth that need enhancement of 




therefore preventing activation. OPG and RANKL are expressed in the gingival 
crevicular fluid within 24 hours post orthodontic force application (25). Future research 
could measure these levels to gain a better understanding of the biology behind tooth 















Figure 1.4: Inhibition of osteoclast activation and bone resorption through the 
binding of OPG to the RANK ligand on an hCO. 
The osteoblast cell has RANK ligands on the cell surface which bind to the RANK 
receptor on the osteoclast precursor cell. Osteoclast activity is upregulated and 
results in increased bone resorption and thus tooth movement. When OPG binds to 
RANKL on the osteoblast, osteoclast activity decreases as it cannot bind to the 
osteoblast via RANKL. This process of osteoclast inhibition also occurs through 
RANK/RANKL receptors on stromal cells. Original work created using 
BioRender.com  
Figure 1.3: Impact of RANKL:OPG ratio on bone resorption. 
Bone resorption is controlled by the ratio of RANKL:OPG. When there is a greater 
concentration of OPG, there is less RANKL available for binding of the RANKL 
receptor on osteoclasts. Therefore, there is less activation of osteoclasts and less 
resorption, as is expected at sites of tension. When the ratio shifts to an increase in 
RANKL with less OPG available, there is an upregulation of osteoclastic activity and 
more bone resorption, as expected in areas of pressure. Created by M Paterson using 





The use of OPG to inhibit OTM was investigated by Dunn et al., in 2007 (26). Using a 
rat animal model, different levels of OPG (0.0, 0.5 and 5.0 mg/kg) were injected twice 
weekly adjacent to the molar tooth to determine the effect of OPG in the hopes that it 
would inhibit tooth movement while orthodontic force was applied. Mesial molar 
movement was inhibited when a high dose of the drug was administered. Unfortunately, 
although the drug was injected near the molar, it also exhibited inhibitory movement 
effects on the incisors. Additionally, the concentration of OPG identified systemically 
had also increased. Animal models investigating the effects on increasing anchorage 
using OPG have given promising results. However, changing the delivery method so that 
the effects of OPG could be delivered solely to the tooth/teeth of interest, rather than a 
local and systemic effect, is desired. 
 
Investigation into an alternative delivery method of OPG has shown promising results. 
One successful delivery method identified is via poly(lactic-co-glycolic acid) (PLGA) 
microspheres. The spheres allow accurate delivery of the drugs to the desired tissue target 
and a reduced concentration of the drug elsewhere. However, this delivery mechanism 
can modify the drug action, pharmacokinetic profile and tissue distribution (27). This 
method of delivery identified only partial inhibition of molar tooth movement compared 
to high dose non-sphere OPG which completely inhibited the mesial movement of the 
molar. However, the low dose sphere did not affect the movement of the incisors and was 
not identified in the systemic circulation (27). Therefore, although total anchorage was 
not achieved; minimizing the potentially toxic systemic drug effects, as seen by Dunn et 
al., (2007), is a significant advantage of this system (26). Again, this research was 
conducted on an animal model. Animal models have increased our knowledge of the 
potential of delivery of OPG on tooth movement, however they do not truly represent 
what is occurring during OTM in a human. Further understanding on bone remodelling 
at a cellular level during OTM if required, particularly in vitro investigation on human 
cells in order to further progress this exciting area of research towards in vivo animal 
models prior to consideration of application in humans.   
 
In order to deliver OPG at an optimum dose and time to the desired location, 
understanding the effect of local cytokines, such as IL-6 and IL-17, on the production of 
OPG, RANK and ALP by hO and hPDLC, and thus their influence on tooth movement 
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is required. In vitro studies identifying the time and dose response of hPDLCs and hO 
cells to IL-17 and IL-6 are vital in increasing our knowledge on the underlying 
mechanisms of tooth movement and bone turnover (28, 29). RANKL expression is 
promoted by IL-17 as identified by Lin et al., (2014). IL-17 also inhibited the expression 
of OPG in hPDLC, and a dose- and time-dependent response was observed (29). A dose-
dependent protein increase of RANKL was observed in Western blot analysis and the 
maximum expression was obtained at 50 ng/ml (29). Further analysis also found that 
mRNA expression of RANKL was enhanced by IL-17 in a time-dependent manner (29, 
30). This increase in RANKL reached a plateau at 24 hours (29). OPG was also seen to 
significantly decrease in vitro at time points 24 and 48 hours. The expression of OPG 
was also shown to decrease in a time- and dose-dependent manner (29). The 
concentrations of RANKL increasing as OPG decreases demonstrates a peak time point 
of bone resorption at 24 hours. Little is known of the effect of IL-6 on the 
RANK,RANKL, OPG axis and is worth investigation. The dose and time response of hO 
and hPDLC to IL-6 and IL-17 will be of significance as this may change the 
concentration and or timepoint of administration of OPG required at the site where 
additional anchorage is required.  
 
1.3 Differences in calvarial and femoral bone formation  
 
Different sites within the skeletal system differ in their embryological origin, mode of 
osteogenesis, response to mechanical strain, mineralisation and resorption patterns and 
osteogenic potential (31). Classic work by Le Lievre, Le Douarin and co-workers on 
chick and quail embryos identified the craniofacial skeleton to be derived from neural 
crest cells (NCC), which migrate to the head region and differentiate via complex 
signalling pathways (32-34). Following migration and differentiation of the NCC bones 
of the craniofacial skeleton are formed via intramembranous or endochondral ossification. 
Intramembranous ossification is the process of direct ossification without a cartilaginous 
precursor and occurs in bones of the craniofacial skeleton, apart from the posterior cranial 
base and condylar head. The remaining skeleton develops by endochondral ossification 
from a cartilage precursor, which later becomes mineralised following apoptosis of 
chondrocytes and replacement with bone by osteoblasts (33, 35, 36). As two different 
sources of osteoblasts are available for in vitro studies, calvarial and femoral, there is the 
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potential for a difference in the regulation of mineralisation and osteogenic potential 
between the two sources. Therefore, the use of calvarial osteoblasts for this study will be 
more representative of the cells present in vivo. 
 
The osteogenic potential and regenerative capacity is thought to be higher in neural crest-
derived bones compared to mesoderm-derived bones (37, 38). The phenotype of iliac 
crest-derived and mandibular human calvarial osteoblasts (hCO) within individual 
patients has been investigated (39). Although a small sample size (N=4), this study 
allowed for direct comparison of the two cell lines within individual patients, while 
limiting the confounding variable of individual variation. Mandibular neural crest-
derived osteoblasts were identified to proliferate faster and showed comparatively higher 
levels of insulin–like growth factor II (IGF-II), higher basic fibroblastic growth factor 
(bFGF) and less alkaline phosphatase (39). It is clear that although both are osteoblasts, 
the site of origin provides stark differences in cellular function. 
 
In summary, differences in embryological origin of calvarial and long bones manifest in 
contrasting bone development processes that are mediated by different regulatory 
molecules. Therefore, due to their differences, it was deemed appropriate to use calvarial 
rather than femoral osteoblasts as a more representative cell line for osteoblasts 
surrounding the teeth during OTM and thus in the following experiments (40).  
 
1.4 Bone remodelling  
 
Throughout life, the skeleton continuously undergoes remodelling and contributes to 
calcium homeostasis, repair of micro-fractures and adaption to mechanical loading. 
Disruption or uncoupling of the bone resorption and apposition sequence is apparent in 
several bone diseases. Bone adapts to variations in mechanical load at both cellular and 
tissue levels resulting in changes in shape of the bone in response to new demands (41). 
Bone remodelling is a coupled process involving the coordinated activity of osteoclasts 
and osteoblasts known as the activation-resorption formation sequence (42). In the late 
1990s, cytokines within the TNF family were identified as the essential components of a 
signalling system that are required for bone remodelling, known as the receptor activator 
of nuclear factor-κB (RANK), RANKL and OPG triad (43, 44). These key components 
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to bone remodelling will be investigated in this thesis to determine the effects of IL-17 
and IL-6 on hPDLC and hCOs.  
 
1.5 Intercellular communication; mono-culture vs co-culture 
 
Intercellular communication allows cells to work together to perform important bodily 
processes that are necessary for survival. For example, mesenchymal stem cells have 
been shown to be induced towards osteogenesis by co-culture with hCOs (45). Cellular 
activity can lead to the secretion of paracrine factors, such as growth factors and 
cytokines, which can modulate the response of adjacent cells. This is evident through the 
action of extracellular signalling proteins, such as interleukin-6 (IL-6) and interleukin-
17 (IL-17). They may act in an autocrine or paracrine fashion and can target nearby cells 
to provide cell-cell communication. This communication can affect bone metabolism and 
thereby, OTM. 
 
At a bone fracture site, the influence of an inflammatory response, immune cells and 
cellular communication associated with bony remodelling is evident. During fracture 
healing, there is first an inflammatory response and an influx of immune cells, such as 
macrophages. Cellular communication between the macrophages and osteoprogenitor 
cells modulates the fracture healing (45). Co-culture with immature macrophage cells 
was shown to enhance the osteogenesis of mesenchymal stem cells through pro-
inflammatory cytokines (interleukins 6,12 and TNFs) and growth factors (TGFs, VEGFs, 
IGFs) (46). It is clear that immune cells are not only involved in bone remodelling, but 
also that the communication between cells is vital for the process to occur.  
 
Cellular response can also be influenced by direct cell-cell contact. This contact can be 
via integrins and cell adhesion molecules. Induction of osteogenesis is believed to be 
regulated by direct cell-cell contact and pro-osteoblastic paracrine factors. Furthermore, 
during tooth movement bone is subjected to mechanical cues of compression and tension 
- culture of cell-seeded constructs within bioreactors that mimic these cues will influence 
osteogenesis (45). It is clear that communication between cells involved in bony 




Cellular communication has been shown to alter the cellular activity of PDLCs and 
osteoblasts, such as the expression of genes Runx2 and P2RX7 (19). It is reasonable to 
expect periodontal, osteoclast and osteoblast cells to communicate throughout OTM. 
ALP activity and gene and protein expression levels of osteogenic markers have been 
identified to increase significantly when hCOs are grown in co-culture with PDLCs 
compared to mono-culture controls (47, 48). Therefore, cells cultured in isolation may 
not replicate the natural surroundings of the PDL. A co-culture system would however, 
allow co-signalling, gene transcription and expression of mediators to be studied in a 
more clinically relevant setting (19). In this study, cellular responses to IL-17 and IL-6 
will be measured, this will include viability assays and gene assays of ALP, OPG, RANK 
and RANKL by hPDLCs and osteoblasts. Comparing the effects of dose- and time-
dependence of a co-culture of hCOs and hPDLCs would be informative in establishing 
whether the dose and time-dependent response of the cells is different or augmented. 
 
Knowledge of bone remodelling has made significant progress. However, further 
knowledge is required of the inductive signals, and in particular their combination and/or 
concentration, will lead to the resorption or deposition of bone. In addition, culturing 
hPDLC and hCOs together in co-culture is a more representative environment of what is 
occurring around the tooth and will be used as an experimental model in the following 
experiments. 
 
1.6 The role of cytokines in bone remodelling 
 
Cytokines are small secreted proteins released by cells and have a specific effect on the 
interactions and communication between cells. Cytokines may act on the cells that 
secrete them (autocrine action), on nearby cells (paracrine action), or in some instances 
on distant cells (endocrine action) (Figure 1.5). Therefore, they can have a significant 
impact on cellular activity and thus bodily processes. 
 
Different cellular functions, such as activation or proliferation can be generated through 
different cytokines. It is also common for different cell types to secrete the same cytokine 
or for a single cytokine to act on several different cell types (pleiotropy). Cytokines are 
often produced in a cascade. One cytokine can stimulate its target cells to make additional 
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cytokines. Cytokines can also act synergistically or antagonistically. This study will 
focus on the cytokines IL-17 and IL-6 and how they impact the viability of hCO and 
hPDLCs cultured in isolation and together and the expression of genes associated with 




Figure 1.5: Cytokine network. 
Different cell types coordinate their efforts as part of the immune system, including B 
cells, T cells, macrophages, mast cells, neutrophils, basophils and eosinophils. Each of 
these cell types has a distinct role in the immune system, and communicates with other 
immune cells using secreted cytokines. Cytokines are illustrated to have an autocrine 
and/or paracrine effect which can result in stimulation of cytokine production, cell 
proliferation and/or activation. Due to the inflammatory like reaction occurring in the 
Periodontal ligament space during orthodontic tooth movement, this communication via 
cytokines, such as IL-17 and IL-6, will affect the activity of both immune cells, and cells 
involved in bone remodelling. Figure adapted from (49). Created using BioRender.com 
 
Orthodontic forces induce an inflammatory like response in the PDL space. During early 
stages of tooth movement, there is an increase in vascular permeability and cellular 




produce inflammatory cytokines that include lymphocyte- and monocyte-derived factors, 
colony-stimulating factors, growth factors, and chemotactic factors (50). Inflammatory 
cytokines such as interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-8, tumour necrosis factor-α 
(TNFα), interferon-γ (IFNγ), and osteoclast differentiation factor have been found in high 
concentrations in the gingival crevicular fluid surrounding moving teeth (51-53). 
However, the role and influence of cytokines, and the concentration of cytokines during 
tooth movement is not clear. Many studies have also reported high levels of IL-17 in the 
peripheral blood, gingival crevicular fluid and inflammatory gingival tissues of 
periodontal patients and that it is associated with periodontal bone metabolism (54-56). 
As OTM also produces an inflammatory like reaction surrounding the tooth, it is valuable 
to study the IL-17 involvement in bone formation and absorption as diagnostic targets 
for better understanding of bone remodelling following the application of orthodontic 
force. 
 
One possible mechanism through which inflammatory cytokines may affect bone 
remodelling is through the recruitment of osteoclast precursors from the circulation, their 
maturation and activation (Figure 1.6). An animal model study (N=48 rats) investigated 
whether stimulating the expression of inflammatory cytokines through small perforations 
of cortical bone increased the rate of bone remodelling and tooth movement when 
orthodontic force was applied. Rats that received force application, plus a flap and three 
small perforations of the cortical plate demonstrated a significant increase in cytokine 
expression, higher numbers of osteoclasts and bone remodelling activity, accompanied 
by generalized osteoporosity and increased rate of tooth movement than those in the 
control group (57). Whilst clearly showing the important influence cytokines have on 
bony remodelling, the surgical burden and additional risks of utilising cortical plate 
perforations in order to stimulate an inflammatory effect must be weighed up with the 
perceived benefit of an increased rate of movement. Whilst a significant increase in 
cytokine expression was identified, this translated to a mean of 0.29mm distal crown 
movement in the orthodontic force only compared to 0.62mm in the group receiving the 
perforations at day 28. Clinically, an increase of approximately 0.3mm tooth movement 
in a rat is significant but this may not necessarily translate to a significant movement in 





Previous research has identified that certain cytokines are key players in bone 
remodelling. Animal models have increased our knowledge of the influence of 
inflammation on tooth movement, however they do not truly represent what is occurring 
during OTM in a human. As the role and influence of cytokines, and the concentration 
of cytokines during tooth movement is not clear, further in vitro investigation is required. 
 
1.7 The role of interleukin-17 in osteoclastogenesis 
 
T helper 17 cells (Th17) are a unique subset of CD4(+) T cells characterised by the 
production of IL-17 (58, 59). Production of IL-17 following activation of Th17 cells 
induces a significant tissue reaction due to the broad distribution of the IL-17 receptors 
(59). Osteoclasts are the main therapeutic targets of IL-17, although there is mounting 
evidence that other cells are influenced by IL-17. This may help in accurate exploration 
of the cellular mechanisms of alveolar bone resorption during OTM (60). These receptors 
are present in the PDL space surrounding the teeth. However, the role of IL-17 and IL-6 
in the balance of osteogenesis and osteoclastogenesis supporting hCO and hPDLC 
activity is unclear. Therefore, bone turnover and ultimate bone levels surrounding teeth 
have the potential to be significantly affected by the presence of IL-17 and warrants 
further investigation. 
 
Th17 cells and IL-17 play a role in multiple autoimmune and inflammatory diseases, 
such as systemic lupus erythematosus, periodontal disease, rheumatoid arthritis, multiple 
sclerosis, and psoriasis (58, 59, 61). The role of IL-17 in the pathogenesis of periodontal 
disease has been well documented. A significant increase in the expression of RANKL 
and inhibition of the expression of OPG by hPDLC following exposure to IL-17 was 
identified by Lin et al., (2014) (29). RANKL and OPG are two critical indicators for 
osteoclastogenesis in formation of bone-resorbing cells from a precursor origin, and thus 
it has been suggested that IL-17 plays an active role in the pathogenesis of periodontal 
bone remodelling (29). It is clear that Th17 cells play a pivotal role in many inflammatory 
diseases and thus knowledge of their role in OTM, and the resulting bone remodelling, 




OTM produces an inflammatory-like environment in the PDL space surrounding the 
teeth. This is, in part, due to Th17 cells responding to OTM by promoting the production 
of inflammatory mediators, such as cytokine IL-17 (20). Osteoblasts have receptors for 
many hormones and growth factors that stimulate bone turnover, including IL-17 
receptors. IL-17 has been identified to not only affect PDLC but also promote bone 
metabolism by stimulating osteogenic differentiation of mesenchymal stem cells and 
osteoblasts (Figure 1.6). IL-17 also promotes pro-osteoclastogenic molecules on 
osteoblasts and mesenchymal stem cells, thus promoting bone resorption (62). Therefore, 
the down-stream effects of IL-17 on both hPDLC and hCOs play a role in a clinician’s 
ability to move teeth following the application of force. 
 
Secretion of interleukin-17 from T-helper cell acts on osteoblast cells inhibiting the 
production of OPG and thus leaving the RANK ligand open to bind to RANK on 
osteoclast precursor cells. This activates the precursor cell to differentiate into an 
osteoclast cell which will result in bone resorption and therefore enable the tooth to move. 
Image created using BioRender.com. 
  
Figure 1.6: Pivotal role of interleukin-17 in osteoclastogenesis. 
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1.8 The role of interleukin-6 in OTM 
 
Interleukin 6 (IL-6) is a multifunctional cytokine that plays an important role in 
osteoclastic bone resorption (21). It belongs to a glycoprotein 130 family which is 
composed of IL-6, interleukin 11, oncostantin M, leukaemia inhibitory factor, 
cardiotrophin-1 and novel neurotrophin-1/B cell stimulatory factor-3 (63, 64). The 
members of this family are characterised by being pleiotropic and sharing the 
glycoprotein chain gp130 as a common signal transducer (63, 65, 66). The significance 
of IL-6 on OTM is evident in the literature through multiple processes. An increase in 
formation of multinucleated cells, such as early osteoblastic precursor cells, when 
cultured in the presence of IL-6 was demonstrated by Kurihara et al. (1990) (67). Later 
on, Abebanjo et al., (1998) reported that IL-6 could also activate mature osteoclasts (68). 
Osteoclastogenesis stimulation by IL-6 has also been shown through stromal or 
osteoblastic cells (69). This is via activation of gp130 in stromal / osteoblastic cells. The 
level of IL-6 in gingival crevicular fluid has also recently been shown to increase during 
OTM (70). It is clear that IL-6 plays an important role in bone turnover and resorption 
during OTM. A dose-dependent relationship between IL-6 and bone remodelling may 
affect OTM. An understanding of this relationship would be of great value with regard 
to reducing treatment duration and thus reduce the risk of root resorption.  
 
Remodelling of the tooth root is a constant feature of OTM. It appears that cementum 
(and dentine if resorption penetrates deep enough) is removed from the root surface, then 
cementum is restored in the same way that alveolar bone is removed and then replaced. 
If repair does not replace the initially resorbed cementum, then there is permanent loss 
of root structure. During orthodontic treatment, many patient and treatment factors 
increase the risk of root resorption. Most cases of root resorption associated with OTM 
involve the cementum of the apex of the tooth. Several studies have indicated that 
patients who undergo treatment of longer duration exhibit more orthodontically induced 
root resorption (OIRR) than patients with a more efficient and shorter duration of 
treatment (71, 72). We must be careful to determine between patients who have had a 
longer active treatment compared to a longer treatment due to missed appointments. 
Missed appointments may increase the length of treatment, but may in fact decrease the 
amount of OIRR. This is due to a longer time between activation of forces associated 
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with their orthodontic treatment. Current evidence suggests that continuous (24 hrs) 
application of orthodontic force generates more OIRR than discontinuous (12 hrs) forces 
(73, 74). Clearly, multiple aspects of orthodontic treatment influence clinical outcomes. 
In the future, it may be possible to use biomarkers to monitor a patient’s individual 
response to force to better predict treatment time and reduce risks such as root resorption. 
 
The level of force applied to teeth throughout treatment is also a well-known factor 
associated with OIRR. Heavy force is associated with greater OIRR than light forces (75, 
76). This is likely due to more areas of hyalinization being generated of the root surface. 
A split mouth study design utilized by Barbagello et al., (2008) investigating OIRR on 
premolars that were to be extracted was conducted. After eight weeks, they found that 
teeth treated with clear aligners and light forces (25g) had approximately the same 
amount of OIRR (five-six times greater than control side). Teeth treated with heavy 
forces (225g) had nine times greater OIRR than the controls (77). The use of heavy and 
continuous forces will produce an inflammatory like reaction surrounding the moving 
tooth roots. Mediators such as IL-6 and IL-17 will be involved and the response of 
hPDLC and hCOs to both the duration and dose of exposure to these cells will impact on 
both the risk of root resorption and potential for negative sequelae following OTM. There 
is the potential to develop individualised treatment where IL-6 could be used as a 
biomarker for detection of high-risk patients for root resorption. This could minimise 
radiation exposure of these patients and ultimately lead to safer orthodontic treatment 
and education for high-risk patients of root resorption.  
 
The ability of cytokines to act as cellular messengers and thus influence behaviours of 
other cells is significant in OTM. A greater understanding of the dose and time points at 
which IL-6 has an effect on both hPDLC and hCOs will improve our understanding of 
OTM and identification of high-risk patients.   
 
1.9 ALP expression by osteoblasts 
 
Alkaline phosphatase (ALP) is required for mineralisation, and detection of mRNA 
expression levels is an important indirect measure of osteogenesis (78). ALP levels 
increase if there is active bone formation occurring. The inhibitory effect of IL-17 on 
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osteoblast calcification can also be measured by the level of ALP activity. Current 
research suggests that hCOs treated with IL-17 and/or Interferon-g (IFN-g) showed no 
increase in proliferation (79). Increased ALP activities, however, have been observed in 
primary osteoblasts treated with IL-17 or IL-17 in combination with IFN-g (78). 
Promotion of expression of genes ALP, Runx2, osteocalcin, OPG and RANKL was 
identified when primary osteoblasts were exposed to IL-17 (78). The known effects of 
IL-17 on osteoblasts are limited. The results from Zhang et al., (2017) contradicted the 
previous study as IL-17 exhibited an inhibitory effect on the gene expression of Alp and 
Runx-2 (79). They identified a downregulated ALP activity and ALP concentration of 
primary osteoblasts by IL-17 in a dose-dependent manner. Determining the dose-
dependent inhibitory effect of IL-17 and IL-6 on the expression of ALP by hCOs would 
be beneficial to create clarity on the effect.  
 
To understand the cellular mechanisms of OTM, it is best to study the cellular 
interactions on primary human cells. As it is not ethical to conduct experiments in vivo, 
therefore an in vitro model will be utilised to determine the effects of IL-17 and IL-6 on 
expression levels of genes associated with osteogenesis by hPDLC and hCOs. This will 
further our knowledge of the cellular activity of two key cells in bony remodelling and 
the effects of cytokines, IL-17 and IL-6, during the inflammatory like reaction which 
occurs when an orthodontic force is applied.  
 
1.10 Laboratory techniques for evaluating hCO and hPDLCs 
 
1.10.1 Tissue sample collection  
 
Extractions are commonly required in orthodontic treatment to correct or camouflage a 
malocclusion. Premolars are commonly chosen for extraction, with second premolars 
often being single rooted, easily accessed, and able to be removed with minimal surgical 
trauma (80). Patients receiving orthodontic treatment range in age, however many 
adolescents between the ages 12-18 are screened for treatment. The chance of the tooth 
being free from pathology, such as caries or periodontal disease, is also greater in a 
younger age range compared to older individuals. Therefore, healthy premolar teeth from 
patients aged between 12-18 was chosen to obtain a suitable number of teeth to be 
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reviewed for examination and PDL explants collected for this study. Following a simple 
extraction, the explant protocol described by Somerman et al., (1988) was used to prepare 
a primary culture of hPDLCs [1].  
  
1.10.2 Viability assays  
 
The assay by PrestoBlueTM is based on the principle of reduction of the non-fluorescent 
reagent (resazurin) to a fluorescent compound (resorufin). This can be detected using 
absorbance measurements and provides a measure of cell viability (81). This conversion 
is proportional to the number of metabolically active cells, but it does not quantify dead 
cells (82). Being a live cell assay, the cells can continue to be cultured and proliferation 
monitored at multiple time points, or the cells can be used for further experimentation 
(83, 84). Studies have compared different commercially available viability agents 
including -iodonitrotetrazolium violet (INT), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) PrestoBlueTM, and AlamarBlueTM as use of growth 
indicators and cell viability reagents (83, 85). They found that both PrestoBlueTM and 
AlamarBlueTM resulted in quick and easily distinguishable colour change that allowed 
for visual readings. The viability of human corneal epithelial cells was assessed via 
several different agents by Xu et al., (2015) and the results suggested that PrestoBlueTM 
was more sensitive than MTT but similar to AlamarBlueTM. An additional advantage of 
PrestoblueTM was that storage of the plate for up to 7 days did not affect the result of the 
assay (83). Due to the advantages of PrestoBlueTM, it was deemed suitable to assess 
viability of hCO and hPDLC at various time points throughout experimentation. This 
technique can be used in both mono- and co-culture experimental set ups. Following its 
use, this assay allowed mRNA to be extracted at each timepoint to investigate gene 
expression by hCO and hPDLCs. 
 
1.10.3 Gene expression studies 
 
The real-time reverse transcription polymerase chain reaction (RT-qPCR) has become 
the method of choice for quantification of mRNA in many medical and scientific 
disciplines (86). This is a fluorescence based, enzyme-driven technique used to 
amplify DNA to a level which can be detected and the associated signal used for 
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quantification. Not only is RT-qPCR a highly sensitive, time efficient and easily 
reproducible technique of RT-qPCR but it also permits analysis of multiple genes (87). 
In this study, it was utilised to identify mRNA expression of RANK, RANKL, OPG and 
ALP genes by hCO and hPDLCs. This assay is commonly used and often described as 
“gold standard”, however it is a highly sensitive technique and the quality of the outcome 
depends on several variables. Problems can arise from variability of RNA templates, 
assay designs and protocols, as well as inappropriate data normalization and inconsistent 
data analysis. To address these issues, protocols of standardization have been described 
and utilised resulting in generation of quantitative data that is reliable and reproducible 
(86).  
 
Several approaches have been utilised in qPCR to detect and amplify PCR product. 
Fluorescent reporter dyes can be used to detect a signal, which is proportional 
to the amount of DNA produced during each PCR cycle. Two detection chemistries are 
available, including SYBR® Green and TaqMan®. Both chemistries generate 
fluorescence during PCR, allowing a real time monitoring of the reaction.  
TaqMan® offers an advantage over SYBR® Green in that it allows two or more 
fluorescent probes labelled with different reporter dyes to be used, which bind to specific 
gene targets. The TaqMan® assay employs sequence-specific probes with fluoresce upon 
probe hydrolysis to detect the amplified product (88). The probe is labelled with a 
reporter dye at the 5’ end, and a quencher dye at the 3’ end (89). During the extension 
step of PCR, the bound and quenched probe are degraded by the DNA polymerase when 
annealed to the target sequence. This permits a separation of the reporter from the 
quencher dye moiety and an increased fluorescent signal (87). Due to the presented 
advantages, TaqMan® hydrolysis was utilised in this present study. 
 
To account for variables amongst samples that may arise during the PCR assay, a control 
gene is utilised to normalise qPCR results, i.e. a housekeeping gene. It is assumed that 
the housekeeping gene remains constant in the cells or tissues under investigation. For 
comparison of gene expression data, a commonly used housekeeping gene is 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The value of GAPDH has been 
investigated in different human tissues identifying the value of this gene as an internal 
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control (90). Within-tissue variation of GAPDH mRNA expression levels in healthy 
tissue was generally small and suitable as a housekeeping gene.  
 
In summary, the use of PCR has been widely accepted for quantification of mRNA. The 
use of the TaqMan® offered increased specificity for the target genes over other 
fluorescent qPCR methods and the housekeeping gene, GAPDH, provided normalisation 
of the results obtained.  
 
1.11 Significance of this research  
 
The ability to move teeth from one point to another is a vital part of orthodontic treatment. 
A clinician’s understanding of the underlying concept of tooth movement allows for the 
potential of decreasing overall treatment time and thus improving patient satisfaction. 
Development of innovative mechanical orthodontic appliances for tooth movement are 
numerous, however injury to the periodontium or prolonged treatment time can result in 
some cases. While considerable progress has been made into the effects of mechanical 
forces on tooth movement, the cellular biology underlying these movements is yet to be 
well understood.  This study will develop an in vitro model in which the cells vital to 
OTM, namely hCO and hPDLC, can interact thus providing a more realistic model for 
the environment present in the PDL. This model would provide a suitable environment 
for investigating the effects of cytokines, IL-6 and IL-17 and their effects in isolation and 
co-culture on hPDLC and hCOs.  
 
Current in vitro experiments involving exposure of hPDLC and hCO to IL-17 and/or IL-
6 have identified an increase in osteoclastogenesis activity. However, clarification of the 
dose and time-dependent response of IL-17 and IL-6 will further this area of research. 
Ultimately, bridging the gap of knowledge of cellular mechanisms behind OTM will 
assist clinicians in the future design and utilisation of orthodontic devices resulting in 






1.12 Aims and objectives  
 
Overall, this project aims to address three main components in bone remodelling in OTM:  
 
i. Determine whether IL-17 and/or IL-6 affect cell viability of human calvarial 
osteoblasts (hCOs) and primary human periodontal ligament cells (hPDLCs);  
a. Determine whether there is a dose and time-dependent response.  
 
ii. Determine whether IL-17 and/or IL-6 affect gene expression of OPG, RANK, 
RANKL, and ALP, within hCOs and hPDLCs;  
a. Determine whether this response is dose and time-dependent.  
 
iii. Investigate the cytokine-mediated intercellular communication between hCOs 
and hPDLCs;  
a. Establish an indirect co-culture system for hPDLCs and hCOs.  
b. Determine whether co-culture enhances or alters cell viability and gene 




We hypothesise that IL-6 and IL-17 will stimulate molecules involved in 
osteoclastogenesis. This will occur through increased levels of mRNA expression of 
RANK and RANKL by hPDLCs and hCOs. Expression of ALP and OPG production by 
hCOs will be decreased.  
 
Additionally, it is hypothesised that expression of RANK and RANKL will be increased 
when the hPDLC and hCOs are grown as a co-culture compared to when they are cultured 
in isolation and thus have a greater effect on bone turnover. 
 
1.14 Ethical approval and Māori consultation  
 
Ethical approval has been granted by the University of Otago Human Ethics Committee 
(Health) (Ref H19/099) (Appendix 7.2). An amendment to the ethical approval was also 
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obtained to increase participant numbers (Appendix 7.3). Māori Consultation has been 
undertaken with the Ngāi Tahu Research Consultation Committee, as this research is 
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2.1 Isolation and culture of periodontal ligament cells  
 
2.1.1 Patient Selection 
Ethical approval from the University of Otago Human Ethics Committee was obtained 
(Reference H19/099, Appendix 1)) and approval was granted by the Ngāi Tahu Research 
Consultation Committee (Appendix 1). Following informed consent, periodontal 
ligament (PDL) tissue was obtained from five healthy, non-smoking adolescents who 
were having teeth removed for orthodontic reasons at the University of Otago (Table 1.1) 
(see Appendix 7.4 and 7.5 for participant information and consent forms). The teeth 
collected were free from caries and periodontal disease. This was determined from 
clinical and radiographic examination.  
 
2.1.2 Primary hPDLC culture 
The explant protocol described by Somerman et al., (1988) was used to prepare a primary 
culture of PDL cells (91).  
 
Following a simple extraction under local anaesthesia, the premolar tooth was placed in 
a 50 mL falcon tube containing 10 mL of supplemented DMEM culture media which 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific, Cat No. 
10566024), 10% foetal bovine serum (FBS) (Life Technologies Cat No A3160902), 0.5% 
v/v gentamicin (Gibco, Life technologies, Cat No. 15710064) and 1% v/v antibiotic-
antimycotic reagent (Thermo Fisher Scientific, Cat No. 15240096) (see Appendix 4 for 
preparation of supplemented DMEM media). The tooth was kept on ice and transported 
to the PC2 laboratory and handled using aseptic technique in a laminar flow chamber.  
 
Using a scalpel blade, PDL tissue was collected from the middle third of the premolar 
root surface (Figure 2.1). Four small pieces of tissue were taken from each tooth and 
placed in the centre of four different wells within a 24-well tissue culture plate (Thermo 
Fisher, Cat No. 142475) containing supplemented DMEM media (300 uL). The plate was 
incubated at 37 °C in a humidified atmosphere with 5% carbon dioxide/95% air, 
additional culture medium was added to each well according the table below (Table 2.1), 











Figure 2.1: Healthy maxillary premolar extracted for orthodontic reasons 
Area indicated is the middle third of the root of the extracted tooth which was 
instrumented for collection of PDL tissue explant. 
 




1 300 µL 
2 500 µL 
3 200 µL 
 
The medium was then changed every three days, and the explants were routinely 
examined under a light microscope (EVOSTM M5000 Imaging system, Invitrogen, Cat 
No. AMF5000) for the presence of outgrowth. 
 
2.1.3 Cell expansion 
When the cells reached 70–80% confluence they were lifted from the 24-well culture 
plates using trypsinisation (Trypsin-EDTA [0.25%]; Life Technologies, Carlsbad, CA, 
USA, Cat No. 25200072) and transferred to a T-25 culture flask. When 80% confluent, 
the cells were expanded into T-75 flasks (see Appendix 7). 
 
2.1.4 Cyropreservation 
When the cells were 80% confluent, the cells were lifted using trypsinisation and 
transferred to a 15 mL centrifuge tube. The media containing the suspended cells was 
centrifuged at 220 g for 5 min at 21 °C and the supernatant removed. The cell pellet was 
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immediately suspended in 3 mL freezing media, consisting of 90% FBS (Cat no. 
A3160902) and 10% dimethyl sulfoxide (DMSO, Sigma-Aldrich, St Louis, MO, USA 
Cat No. D4540). The cells were immediately transferred to three cryovials (2 mL; 
Greiner Bio-One, Cat No. GR1266-2GD). The cryovials were then placed in a freezing 
container (Mr Frosty™, Nalgen Labware, Rochester, USA), and held at room 
temperature, before placing in the -80°C freezer.  
 
2.1.5 Reanimation of cryopreserved hPDLCs 
Cryovials were removed from the -80 °C freezer and gently warmed in a 37 °C water 
bath. The defrosted cells were then transferred to a T-25 culture flask containing 4 mL 
pre-warmed culture media. The flask was then placed in a 37 °C incubator with 
humidified atmosphere containing 5 % carbon dioxide and 95 % air. After 24 hrs the 
cells were observed using a microscope for confirmation of attachment to the bottom of 
the flask, the culture media was replaced to ensure the DMSO present in the freezing 
media was removed. When 80 % confluent, the cells were lifted using trypsinisation and 
transferred to a T-75 culture flasks for cell expansion. The media was changed every 
three days. 
 
2.2 Reanimation of Human Calvarial Osteoblasts 
 
A commercial human osteoblast cell line was purchased in 2015 from ScienCell 
Research Laboratory (Cat No. 4600, lot 3439). This cell line was of neural crest origin 
and cryopreserved at P1 at >5x105 cells / ml per vial. The osteoblasts originated from 
foetuses (20-22 weeks old) and had a doubling time of 25 hours.  
 
When required, the cells were thawed and cultured in T-25 flasks. Osteoblasts were 
expanded in supplemented DMEM media, which contained DMEM with GlutaMAXTM, 
antibiotic-antimycotic reagent containing penicillin, streptomycin and amphotericin B 
(Thermo Fisher Scientific, Cat no. 15240096), gentamycin and 10% foetal bovine serum 
(FBS) (Appendix 5.6). Before reaching 60-80 % confluence, cells were trypsinised and 




When the cells were 80% confluent, the cells were lifted by trypsinisation as per section 
2.1.4. The cells were immediately transferred to three cryovials (2mL; Greiner Bio-One, 
Cat No. GR1266-2GD). The cryovials were then placed in a freezing container (Mr 
Frosty™, Nalgen Labware, Rochester, USA), held at room temperature, before placing 
in the -80 °C freezer. After 24 hrs the frozen cells were transferred to liquid N2 for long-
term storage.  
 
2.3 Cell counting using a haemocytometer 
 
Samples were centrifuged at 220 x g for 5 min at 21 oC and the supernatant was removed. 
The cells were resuspended in 5 mL of 1 % FBS culture medium and 10 µL was then 
removed from each sample, mixed with 10 µL trypan blue, and cells were counted using 
a haemocytometer. When stained with Trypan Blue, live cells under the microscope 
appear transparent. Dead cells take up the stain and appear blue. The cells were 
centrifuged again at 220 x g for 5 min at 21oC and the supernatant was removed. The 
cells were then ready for experimentation.  
 
2.4 Resuspension of IL-17 and IL-6  
 
A stock solution of IL-17 (Cat no. PHC9174, GibcoTM) was prepared prior to 
experimentation. IL-17 was resuspended in sterile H2O using a 0.22 μm filter attached to 
a 10 mL sterile syringe. This created a stock concentration of 10 µg / 1 mL (10 ng / 1 
µL). Aliquots of 250 µL were transferred to 1.5 mL microfuge tubes and placed in a -
20 °C freezer. This was repeated for IL-6 (Cat no. PHC0065, GibcoTM).  
 
The concentration of IL-17 and / or IL-6 required for each experiment was determined 
using the calculations in Appendix 5.11 and added to the supplemental media required 
for experimentation.   
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2.5 Monolayer experiment plate layout - IL-17 and IL-6 dose response 
experiment  
 
For all experiments one hCO and one hPDLC vial (per biological replicate) were thawed 
in a 37  ̊ C water bath and immediately transferred to a T-25 flask, containing 
supplemented DMEM media and cultured until the cells were 80% confluent and 
passaged into a T-75 flask. Once 80% confluent, the hPDLC and hCOs were then 
trypsinised, counted and seeded at 1x105 cells per well and cultured in monoculture and 
1x106 and co-culture setups as described in 2.2 and 2.3.  
 
hPDLC and hCOs were seeded separately in 24-well plates at a density of 5 x 104 
cells/well with 0.5 mL of supplemented DMEM containing 1% FBS and incubated for 
12 hours before the addition of IL-17 or IL-6.  
 
2.5.1 PDL plate layout 
A total of five 24-well plates per hPDLC line were used. This enabled each cell line to 
be cultured for the five time points (2, 6, 24, 48, 72 hrs). Each plate contained two 
different hPDLC primary cultures incubated with a range of interleukin doses in triplicate 
(Figure 2.2).  
 
Plate 1 
hPDLC 1 hPDLC 2 
replicate 1 replicate 2 replicate 3 replicate 1 replicate 2 replicate 3 
conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  
0 0 0 0 0 0 
25 25 25 25 25 25 
50 50 50 50 50 50 
75 75 75 75 75 75 
 
Figure 2.2: Representative experimental layout of a 24-well plate 
Experimental layout of 24-well plate with two hPDLC primary culture cell lines, each 




2.5.2 HCO plate layout 
hCO experiments were run with and without triple supplement for each concentration in 
triplicate (Figure 2.3). Triple supplement was made with 2-phospho L-ascorbic acid 
(Sigma 49752, soluble in water at 0.3 g/10 mL), dexamethasone (Sigma D2915, soluble 
in water at 25 mg / mL) and β-glycerophosphate (Sigma G9422, soluble in water at 10 
mg/mL) dissolved in sterile MQ H2O (Appendix 7.7). This was added to the 1% FBS 
culture media for each concentration of interleukin and then added to the wells at the start 
of the experiment.  
 
Plate 1 
hCO/1 (without TS) hCO/2 (with TS) 
replicate 1 replicate 2 replicate 3 replicate 1 replicate 2 replicate 3 
conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  conc ng/ml  
0 0 0 0 0 0 
25 25 25 25 25 25 
50 50 50 50 50 50 
75 75 75 75 75 75 
 
Figure 2.3: Representative hCO monoculture experimental layout in 24-well plate 
Four doses of interleukin (IL-17 or IL-6) were added in triplicate to each experimental 
replicate. Triple supplement was added to wells on the right (with TS). 
 
2.6 hPDLC and hCO seeding in co-culture 
 
hPDLCs were seeded in 24-well plates at a density of 5 x 104 cells/well, and hCOs at 1 
x 104 cells/insert were seeded in ThinCertTM cell culture inserts (pore size, 1.0 μm; culture 
area, 113.1 mm2; Greiner Bio-One, Frickenhausen, Germany). The 1.0 μm insert pores 
prevented cross-membrane migration of the cells. Prepared culture media (0.5 mL) 
containing 1% FBS was added to each well. Fresh culture medium and cytokines were 
provided 24 hours after cells were seeded and supernatants were collected after 48 hours. 






Figure 2.4: Schematic representation of mono-culture (1,2) and co-culture (3) 
experimental setups 
Schematic representation of experimental set up of monoculture of (1) hPDLCs and (2) 
hCOs seeded in 24-well plate at 5 x 104 cells/well . (3) Co-culture with hPDLC seeded 
in 24-well plate and hCOs seeded in ThinCertTM cell inserts.  
 
 
 Plate 1 - T48 
 hPDLC 1 / hCO 1 without TS hPDLC 1 / hCO 1 with TS 
  0 ng/ml 0 ng/ml 0 ng/ml  0 ng/ml 0 ng/ml 0 ng/ml 
IL-17 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 
IL-6 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 
Both 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 75 ng/mL 
 
Figure 2.5: Representative hPDLC-hCO co-culture experimental layout.  
Layout duplicated for two remaining hPDLC biological replicates.  
Experimental set up of 24-well plate with hPDLCs cultured in wells and hCO cultured 
in ThinCertTM cell inserts (Greiner Bio-One, Frickenhausen, Germany). Cells were 
cultured with a combination of recombinant human IL-17 and IL-6 (each at a 
concentration of 75 ng/mL) or separately cultured with recombinant human IL-17 or IL-
6 at 75 ng/mL. Experimental conditions included with and without triple supplement (TS). 
Cells were cultured on the 24-well plate for 12 hrs prior to the addition of IL-17 and/or 
IL-6 and then cultured for a total of 48 hrs prior to analysis.  
 
2.7 Cell Viability Measurement 
 
Cell viability was determined at five time points (2, 6, 24, 48 and 72 hrs) for the 
monoculture experiments, and at 48 hrs for the co-culture experiments. PrestoBlue™ 
Figure SEQ Figure \* ARABIC 4: Schematic of the experimental setup of mono and co-
culture wells of PDL and HCO cells. Figur  adapted fr m Shi t al., (2019) 
48 
 
(Invitrogen, Cat No. A13262) is a resazurin based fluorescent dye. When reduction of 
resazurin occurs, it forms a fluorescent pink compound, which quantitatively reflects 
metabolic cell activity (85).  
 
For all co-culture experiments, the inserts were transferred to a fresh 24-well plate 
following 48 hours of incubation and PrestoBlue™ dye added at a 1:10 ratio with 
supplemented culture media. This allowed for viability testing of the insert and well 
separately.  
 
Viability measurements were collected at 48 hrs. A control of 0 ng IL-17 and IL-6 was 
used.  
 
2.8 RNA extraction from cells  
 
The media from each well was transferred to a 1.5 mL microfuge tube and stored in a  
-80 °C freezer for future analysis. The attached cells were then washed with 100 uL PBS. 
TRIzol® (Life Technologies, Cat No. 15596-026) (300 uL/well or 100 uL/insert) was 
added detaching the cells. The resulting homogenate was then transferred to a 1.5 mL 
microfuge tube and stored at -80˚C until required. 
 
2.9 RNA purification  
 
The cell/ TRIzol® homogenates were thawed at room temperature and total RNA isolated 
using the Directzol RNA Miniprep kitTM (Ngaio Diagnostics Limited, Cat No. R2052)  
according to the manufacturer’s instructions. Removal of DNA from RNA samples was 
completed with DNase 1 treatment prior to RT-PCR application (Appendix 7.14). 
 
2.10 Gene expression analysis  
 
Quantitative real-time polymerase chain reaction (qRT2-PCR) assays were used to 
determine the level of mRNA expression for each of the bone metabolism-related genes 
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ALP, RANK, RANKL and OPG. Expression levels of the housekeeping gene GAPDH was 
determined for comparison. 
 
RNA was diluted (1:10) with DNase/RNase-Free water. A master mix for each gene 
assay was prepared which included TaqMan FAST Virus 1-step master mix (4x; 2.5 µL), 
gene of interest primer set (20x: 0.5 µL), RNA (1:10; 5 µL) and DNase/RNase-free water 
(2 µL) to a final volume of 10 µL. Each gene assay was analysed in duplicate using qRT2-
PCR assay. DNase/RNase-free water (5 µL) was used as a negative control replacing the 
RNA sample. A representative experimental layout of the qRT2-PCR plate is shown in 
Figure 2.6. Each of the three biological replicates was run on a separate plate.  
 
PCR amplification was performed on an Applied Biosystems QuantStudio 6 ABI 7500 





Figure 2.6: Experimental layout of RT-qPCR 96 well plate for one hPDLC sample in the presence of 0 or 75 ng/mL IL-17 and/or IL-6 at 
48 hours in co-culture with hCOs 
Example of qPCR 96 well plate experimental layout. Gene assays GAPDH, RANK, RANKL, OPG and ALP were investigated. Assays were 
prepared using mRNA extracted from four hPDLC primary cell lines cultured in the presence of 75 ng/mL IL-17 and/or IL-6 for 48 hrs. hPDLCs 
had been cultured in co-culture with hCOs, with hPDLCs in the well of the 24-well plate and hCOs in the insert. The wells in light green indicate 
that no TS was present in culture media, and dark green indicate that TS was present in culture media. A control for each gene assay was 
conducted using DNase/RNase-free water, as indicated. All mRNA samples were measured in duplicate using qPCR for each gene-interleukin 
type-culture combination.  
 
1 2 3 4 5 6 7 8 9 10 11 12
A hPDLC Untreated hPDLC Untreated hPDLC Untreated hPDLC Untreated hPDLC Untreated
B hPDLC IL-17 hPDLC IL-17 hPDLC IL-17 hPDLC IL-17 hPDLC IL-17
C hPDLC IL-6 hPDLC IL-6 hPDLC IL-6 hPDLC IL-6 hPDLC IL-6
D hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6
E hPDLC Untreated hPDLC Untreated hPDLC Untreated hPDLC Untreated hPDLC Untreated 
F hPDLC IL-17 hPDLC IL-17 hPDLC IL-17 hPDLC IL-17 hPDLC IL-17
G hPDLC IL-6 hPDLC IL-6 hPDLC IL-6 hPDLC IL-6 hPDLC IL-6
H hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6 hPDLC IL-17+IL-6
RANKL OPG ALP
CONTROL - GAPDH +H20
CONTROL - RANK +H20
IL-17 and IL-
6          T48 
GAPDH RANK
CONTROL - RANKL + H20
CONTROL - OPG +H20
CONTROL - ALP +H20
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2.11 Statistical analysis  
 
Graphpad PRISM (version 7) was used for the preparation of graphical figures and 
statistical analysis. Statistical analyses used for specific results are indicated on figure 
legends. 
 
Evaluation between groups of intervention versus control was completed. Multiple 
sample groups were compared using one-way analysis of variance (ANOVA) for 
comparison of variables independent of each other. Normally distributed sample groups 
were analysed using Turkey’s post-hoc test. A p value of <0.05 was considered 
statistically significant.   
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3.1 Patient selection 
 
To understand the cellular mechanisms of OTM, it was best to study the cellular 
interactions on primary human cells. Therefore, a single tooth each was collected from 
five patients who were undergoing orthodontic treatment at the University of Otago. All 
five participants were male, between the ages of 12-14, of European descent and had a 
second premolar tooth extracted (Table 3.1). Two extracted teeth were from the maxilla 
and three from the mandible. All extracted teeth were free of pathology to avoid 
differential gene expression in diseased teeth. 
 
Table 3.1 : Patient demographics 
Sample # Patient age  
(years / months) 
Gender Ethnicity Tooth number 
1 13 / 7 M European 35 
2 13 / 2 M European  25 
3 12 / 0 M European 35 
4 13 / 3 M European 25 
5 13 / 0 M European 35 
 
3.2 Establishment of explant cultures 
 
PDL explants were obtained from the middle third of the extracted teeth and placed in 
the well of a 24-well plate. Cell suspensions were routinely examined under a light 
microscope to determine the presence of cells and their confluence (Figure 3.1, 3.2). 
hPDLCs were detected under the light microscope after 3-5 days for all five explant 
tissue samples. After 12-14 days all five cell cultures were 60-80% confluent, at which 
point the cells were lifted and moved to larger flasks. A commercial human osteoblast 
cell line was purchased in 2015 from ScienCell Research Laboratory. When required, the 
cells were thawed and cultured in T-25 flasks, reaching 60-80% confluency in 














Figure 3.1: Human periodontal ligament cells cultured from PDL explants of 
extracted premolar teeth  
PDL tissue was obtained and processed from the middle third of healthy premolar teeth 
for hPDLC extraction. Resulting cell suspensions were cultured for up to 14 days before 
being transferred from the 24-well plate to a T25 flask. This brightfield image shows 
cellular outgrowth from the PDL explant tissue on the left hand side of the 












Figure 3.2: Human periodontal ligament cells cultured from PDL explants of 
extracted healthy premolar teeth at Day 24 
Brightfield image showing cell morphology of hPDLCs that have been cultured in a 
T75 flask, 24 days following the PDL explant being obtained. The hPDLCs have 
attached to the plate and reached 60-80% confluency. Image taken under 10x 
















Figure 3.3: Human calvarial osteoblasts cultured from a commercial cell line 
hCOs were obtained from a commercial cell line. Cells were thawed and suspended in a 
T25 flask when required. This brightfield image shows hCO morphology after 48 hrs 
culture. hCOs have attached to the flask and have extended their filopodia to form a network 
with each other and with the surrounding extracellular environment at 48 hrs following 
suspension. Image taken under 10x objective lens.  
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3.3 hPDLC and hCO viability 
 
Cell viability assays were conducted to determine an appropriate timepoint for future 
experiments in which gene assays would be investigated. We also aimed to establish 
whether IL-17 or IL-6 affected cell viability in hPDLC and if TS in combination with 
these cytokines affected cell viability in hCOs. Cell viability when cultured as 
monocultures in the presence of 0, 25, 50 or 75 ng/mL IL-6 or IL-17 was determined 
using the PrestoBlueTM over 72 hrs. All resulting fluorescent unit values are available in 
Appendix 7.15.  
 
When cultured as co-cultures with the hPDLC seeded in the wells and the hCO in the 
inserts, cell viability was determined for each cell type, in the presence of 75 ng/mL IL-
17 and/or IL-6 at 48 hrs. This experimental setup allowed for investivation of the effects 
of cellular communication on cell viability of hCOs and hPDLCs in the presence of IL-
17 and/or IL-6. All resulting fluorescent values are available in Appendix 13c and 13d.   
 
3.3.1 Cellular viability in monoculture  
 
3.3.1.1 hPDLC viability when cultured in monolayer (2D) in the presence of IL-17 and/or 
IL-6 
Over 72 hrs, hPDLC viability increased significantly, however, this was not affected by 
the presence or concentration of IL-6 (p=<0.0001***, F=16) (Figure 3.4A). Pairwise 
comparison identified this increase to be significant between 2 and 72 hours (p=0.004**). 
There was also a significant interaction between time and cell viability of hPDLCs, 
regardless of the concentration of IL-17 added to culture media over the 72 hour period 
(p=<0.0001***, F=16.0) (Figure 3.4B). Pairwise comparison identified a statistically 
significant increase in cell viability between 2 and 48 hours (p=0.004**). At each 
timepoint, no significant difference was identified in cell viability and the concentration 
of IL-17 or IL-6 in comparison to untreated cells (0 ng/mL of interleukin). Cell growth 
slowed from 48-72 hours in the presence of IL-17, but cell viability did not reduce 








Figure 3.4: hPDLC viability in the presence of IL-6 or IL-17 in monoculture 
IL-17 or IL-6 was added to wells at 0, 25, 50 or 75 ng/mL, as indicated. (A) addition of 
IL-6 only, (B) addition of IL-17 only. Data shown represents the change in cell viability 
over 72 hrs as a percentage of cell viability measured at baseline (2 hours following 
addition of IL-17 or IL-6). The dotted line represents the baseline cell viability measured 
at 2 hours. Data points at timepoints 2,6,24,48 and 72 hrs represent the mean (+/- SD) 
for the four primary hPDLC lines analysed. 
 
3.3.1.2 HCO viability when cultured in monolayer (2D) in the presence of IL-17 and/or IL-
6 with and without triple supplement. 
 
hCO viability increased significantly over 72 hrs without the presence of TS in 
supplemented culture media (p=<0.0001***, F=15.4) (Figure 3.5A). Cell viability 
increased between 2 and 48 hours (p=0.008**) and also 2 and 72 hours (p=0.036*) 
(Figure 3.5A). In the presence of TS, hCO viability increased significantly 
(p=<0.0001***, F=16.0) (Figure 3.5B). Pairwise comparison identified a significant 
increase in cell viability between 2 and 48 hours (p=0.004**). A lower cell count was 
identified at 72 hours for hCO than 48 hours (with or without TS). The presence and 
concentration of IL-17 did not affect hCO viability over 72 hrs at any time point, with or 
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(A) IL-6 concentration
✱✱
Figure X: PDL cell viability in the presence of 0, 25, 50 or 75 ng/ mL IL-6 or IL-17 in monoculture. 
(A) Addition of IL-6 (B) addition of IL-17. Each data point is the mean (+/- SD) of 4 primary PDL cell 








Figure 3.5: hCO viability in the presence IL-17 in monoculture  
Interleukin-17 was added to wells at 0, 25, 50 or 75 ng/mL with and without TS, as 
indicated. (A) addition of IL-17 only, (B) addition of IL-17 and TS. Data shown 
represents the change in cell viability over 72 hrs as a percentage of cell viability 
measured at baseline (2 hours following cell seeding). The dotted line represents the 
baseline cell viability measured at 2 hours.  Data points at timepoints 2,6,24,48 and 72 
hrs represent the mean (+/- SEM) for one primary hCO cell line (T=3). 
 
In the presence of IL-6, without TS in supplemented media, hCO viability increased 
significantly from 2-48 hrs (p=0.008**) and 2-72 hrs (p=0.037*) but from 48 to 72 hrs 
hCO viability did not increase (Figure 3.6A). The addition and concentration of IL-6 (Fig. 
3.6A) and IL-6 + TS (Fig 3.6B) did not alter hCO viability between 2 and 72 hours. When 
hCO were cultured in the presence of TS, there is a statistically significant increase in 
cell viability over 72 hrs (p=<0.0001***, F=16.0) (Figure 3.6B). Pairwise comparison 
identified a significant increase in cell viability between 2 and 72 hours (p=0.004**). 
Cell growth slowed between 48-72 hrs without TS (p=0.060) and with only a slight 
increasing trend with TS (p=0.999) compared to the initial 48 hrs of cell culture.  
 
These data suggest that 48 hours is an appropriate timepoint for measuring future 
experiments as cell viability has not plateaued. Further, IL6, IL17, and TS did not 
significantly alter cell viability in monoculture of hCOs and PDLCs. 
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75 ng / mL
(B) IL-17 concentration + TS
✱✱
Figure X: HCO cell viability in the presence of 0, 25, 50 or 75 ng/mL IL-17.  Cell count normalised as a 
% of two ho rs.  Each data point expressed as th  mean (+/- SE) of three experimental replicates of 
one HCO cell line (T=3). Data points represent cell viability at time 2, 6, 24, 48 and 72 hours. (A) HCO 






Figure 3.6: hCO viability in the presence of IL-6 in monoculture  
Interleukin-6 was added to wells at 0, 25, 50 or 75 ng/mL with and without TS, as 
indicated. (A) addition of IL-6 only, (B) addition of IL-6 and TS. Data shown represents 
the change in cell viability as a percentage of cell viability measured at baseline (2 hours 
following cell seeding). The dotted line represents the baseline cell viability measured at 
2 hours.  Data points represent the mean (+/- SEM) for one primary hCO line (T=3). 
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0 ng / mL
25 ng / mL
50 ng / mL
75 ng / mL
(B)
IL-6 concentration + TS
✱✱
Figure X: HCO cell viability in the presence of 0, 25, 50 or 75 ng/mL IL-6.  Cell count normalised as a 
% of two hours.  Each data point espressed as the mean (+/- SE) of three experimental replicates of 
one HCO cell line (T=3). Data points represent cell viability at time 2, 6, 24, 48 and 72 hours. (A) HCO 
in monoculture without TS (B) HCO in monoculture with TS 
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3.3.2 hPDLC and hCO viability when co-cultured in the presence of IL-17 and/or 
IL-6 with and without triple supplement. 
 
Monoculture viability assays showed cell growth had not plateaued by 48 hrs and the 
addition or IL-6 or IL-17 did not affect cell viability for either the hCO and hPDLCs. 
Cell growth was also shown to slow between 48-72 hrs in the monoculture assays 
compared to the initial 48 hrs of culture. The dose of 75 ng/mL IL-17 or IL-6 was shown 
not to be cytotoxic or reduce cell viability of hPDLC or hCO over 72 hrs in monoculture. 
Therefore, 48 hrs and 75 ng/mL IL-17 or IL-6 was chosen as the timepoint for the co-
culture analysis and concentration of cytokine for future investigation.  
 
3.3.2.1 hPDLC viability  
Despite a trend towards reduced viability of hPDLCs when cultured in the presence of 
TS compared to without TS (p=0.393, F=1.1), this was not significant. The addition of 
IL-17 and/or IL-6, with or without TS, at 48 hrs has no significant effect on hPDLC 
viability in comparison to untreated cells (Figure 3.7).   
 
 
Figure 3.7: hPDLC viability at 48 hours  
hPDLCs were cultured in the presence of 75 ng/mL IL-6 and/or IL-7 with TS (light grey) 
and without TS (dark grey), as indicated. A control of 0 ng/mL was used for comparison. 
hPDLC were cultured in co-culture with hCOs. Data shown represents hPDLC viability 
































































3.3.2.2 hCO viability  
 
hCOs were seeded in the transwell insert of a 24-well plate in the presence of 75 ng / mL 
IL-17 and/or IL-6 with or without TS for 48 hrs. IL-17 and/or IL-6 alone did not increase 
hCO viability when no TS was present in supplemented media. However, when TS was 
present, IL-17 significantly increased hCO viability compared to untreated cells 
(p=0.049*). IL-6 alone did not significantly increase hCO viability, but IL-6 plus IL-17 
did (p=0.007**). A statistically significant increase in hCO viability was identified 
between untreated cells (without TS) and 75 ng/mL IL-17 and IL-6 (p=0.011*) (Figure 
3.8).  
 
From these data, it is clear that IL-17 and/or IL-6 alone do not affect hCO viability at 48 
hrs. TS was also shown not to have an effect in isolation but when combined with IL-17 
alone or IL-17 plus IL-6, a significant increase in cell viability is evident.  
 
 
Figure 3.8: hCO viability at 48 hours  
hCOs were cultured in the presence of 75 ng/mL IL-6 and/or IL-7 with TS (light grey) 
and without TS (dark grey), as indicated. A control of 0 ng/mL was used for comparison. 
Data shown represents hCO viability at 48 hrs. Results are expressed as mean 
fluorescence of three experimental replicates for one primary cell line (N=1, T=3) +/- 





























































Untreated vs. IL-6 + IL-17 +TS -44419 -80699 to -8138 Yes * .011 A-H
Untreated + TS vs. IL-17 +TS -36339 -72619 to -58.1 Yes * .049 E-F
*
*




3.4 mRNA expression levels following addition of IL-6 and/or IL-17  
 
Following viability assays, cell RNA was collected and processed for further analysis of 
gene expression of RANK, RANKL, OPG and ALP using RT2 -qPCR assays. mRNA 
expression was determined for the four primary PDL cultures and the one representative 
primary hCO culture. Cells were cultured as monocultures in the presence of 0, 50 or 75 
ng/mL IL-6 or IL-17 and as co-cultures with 75 ng/mL IL-6 and/or IL-17. The cells were 
harvested at 48 hrs. The aim of these experiments was to determine if cytokines IL-17 
and/or IL-6 affect the expression of genes associated with osteogenesis. It was 
hypothesized that the hPDLC and hCO expression levels of RANK and RANKL would 
increase and the levels of OPG and ALP would be reduced when cultured in the presence 
of IL-17 and/or IL-6 as these cytokines are thought to promote bone resorption.  
 
The reference gene GAPDH was used to determine adequate levels of mRNA for both 
hPDLC and hCOs. The expression level of GAPDH (Cq 19–26) measured for each of 
the purified RNA samples indicated sufficient RNA for the analysis of genes of interest 
using RT2-qPCR assays (Figure 3.9). A Cq value of 40 was assigned to samples with no 
detectable mRNA. All Cq values are available in Appendix 7.16. Cq values were 







Figure 3.9: Expression of reference gene GAPDH for hPDLC and hCOs at 48 hours 
Cells cultured in the presence of 0 or 75 ng /mL of IL-17 or IL-6 in monoculture 
(trianglular data points) or co-culture (circular data points). In co-culture, cells were 
cultured with or without TS. Untreated cells with 0 ng/mL IL-17 or IL-6 were used for 
comparison (red data points). Data shown represents mean mRNA expression of GAPDH 
by hCO and hPDLC cells at 48 hrs. Results are expressed as the mean Cq value of four 
primary hPDLC lines (N=4. T=3) +/- SD and the mean Cq value of three experimental 
replicates for one primary hCO line (N=1, T=3) +/- SEM.  



























































































































Cell culture conditions  
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3.4.1 hPDLC mRNA expression following exposure to IL-17 or IL-6 in monoculture 
 
hPDLC mRNA expression levels for RANK, RANKL, OPG and ALP in the presence of 
0, 50 or 75 ng/mL IL-17 or IL-6 at 48 hrs were determined.  
 
3.4.1.1 Expression of RANK mRNA 
The level of expression of RANK mRNA by hPDLC increased when cultured in the 
presence of an increasing concentration of IL-17, however it did not reach significance 
(p=0.127, F= 2.6) (Figure 3.10A). RANK mRNA expression remained low and were 
undetected for three of the four cell lines when cultured with no IL-17 and two of the 
four cell lines with 50 ng/mL. The overall change in expression of RANK mRNA with 
increasing concentration of IL-6 was significant (p=0.050*, F=4.2). With the addition of 
75 ng/mL IL-6 RANK expression significantly increased compared to 50 ng/ml 




Figure 3.10: Expression of RANK mRNA by hPDLCs in monoculture at 48 hours 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL, as indicated. (A) addition of IL-
17, (B) addition of IL-6. Data shown represents the change in RANK mRNA expression 
at 48 hrs by qPCR. Each data point represents the 2^-delta Cq value (+/- SD) for one 
primary hPDLC line (N=4, T=3) expressed as mean +/- SD. Limit of detection indicated 
by broken line.   





















































3.4.1.2 Expression of RANKL mRNA 
A dose response to IL-17 was observed for hPDLC RANKL expression, although not 
significant (p= 0.105, F= 2.9) (Figure 3.11A). When cultured in the presence of IL-6, 
RANKL mRNA was not detected in 18 of 24 samples analysed following 40 cycles of 
qPCR. When mRNA was detected, there was no significant difference in RANKL 
expression between 0 and 75 ng/mL (p=0.353, F=1.0) (Figure 3.11B). Good levels of the 





Figure 3.11: Expression of RANKL mRNA by hPDLCs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL, as indicated. (A) addition of 
IL-17, (B) addition of IL-6. Data shown represents the change in RANKL mRNA 
expression at 48 hrs by qPCR. Each data point represents the 2^-delta Cq value (+/- SD) 
for one primary hPDLC line (N=4, T=3) expressed as mean +/- SD. Limit of detection 




























































3.4.1.3 Expression of OPG mRNA  
High levels of OPG mRNA expression were detected. The expression level of OPG did 
not change with increasing doses of IL-17 (p=0.321, F=1.3) or IL-6 (p=0.780, F=0.3) 
when compared to untreated cells (Figure 3.12A, 3.12B). The addition of 75 mg/ml of 
IL-17, did however elicit some effect on the hPDLCs expression of OPG, however this 




Figure 3.12: Expression of OPG mRNA by hPDLCs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL, as indicated. (A) addition of IL-
17, (B) addition of IL-6. Data shown represents the change in OPG mRNA expression at 
48 hrs by qPCR. Each data point represents the 2^-delta Cq value (+/- SD) for one 
primary hPDLC line (N=4, T=3) expressed as mean +/- SD. Limit of detection indicated 






















































3.4.1.4 Expression of ALP mRNA 
hPDLC ALP mRNA expression levels increased significantly (P=0.029*, F=5.4) with an 
increasing IL-17 dose (Figure 3.13A). Pairwise comparison identified a statistically 
significant increase in expression between 0 and 75 ng/mL (4-fold, p=0.042*). When 50 
ng/ml was compared to 75 ng/mL a difference in ALP expression approaching 
significance was also found (p=0.053). An increasing dose of IL-6 resulted in no 




Figure 3.13: Expression of ALP mRNA by hPDLCs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL, as indicated. (A) addition of IL-
17 only, (B) addition of IL-6 only. Data shown represents the change in ALP mRNA 
expression at 48 hrs by qPCR. Each data point represents the 2^-delta Cq value (+/- SD) 
for one primary hPDLC line (N=4, T=3) expressed as mean +/- SD. Limit of detection 

























































3.4.2 hCO mRNA expression following exposure to IL-17 or IL-6 in monoculture. 
A single representative primary osteoblast culture was used with three experimental 
replicates performed. The gene expression for RANK, RANKL, OPG and ALP following 
the addition of 0, 50 or 75 ng/mL IL-17 or IL-6, was determined at 48 hrs. The addition 
of triple supplement to the culture media was also investigated.  
 
3.4.2.1 Expression of RANK mRNA 
In the absence of TS, no effect of cytokines was found on the level of RANK mRNA 
expression. However, in the presence of TS and with an increasing IL-17 dose, a 
significant increase of RANK mRNA expression was found (F=6.7 p=0.003**; 0 and 75 
ng/mL IL-17 (p=0.007**); 50 and 75 ng/mL (p=0.0167*) (Figure 3.14A). In the presence 
of 75 ng/mL IL-17, the expression level of RANK mRNA was found to be significantly 
increased when also cultured in the presence of TS (p=0.0064**). No significant 




Figure 3.14: Expression of RANK mRNA by hCOs in monoculture at 48 hours 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. (A) addition of IL-17, (B) addition of IL-6. Data shown represents 
the change in RANK mRNA expression at 48 hrs by qPCR. Each data point represents 
the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one primary 











































































3.4.2.2 Expression of RANKL mRNA 
RANKL mRNA was expressed at very low levels. Good levels of the reference gene 
GAPDH were detected in all of the RNA samples assayed indicating good RNA quality. 
 
There was no significant change in RANKL expression with increasing doses of IL-17 in 
the absence of TS (p=0.493, F=0.7) or when TS was added to the media (p=0.251, F=2.0) 
when compared to untreated cells (Figure 3.15A).   
 
The presence of IL-6 did not significantly alter the expression level of RANKL mRNA 
when TS was absent when compared to untreated cells (p=0.872, F=0.1) (Figure 3.15B). 
When TS was added to the media, a decrease in RANKL expression was observed 
although not significant. With the addition of IL-6, and in the present of TS, a small 




Figure 3.15: Expression of RANKL mRNA by hCOs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. (A) addition of IL-17, (B) addition of IL-6. Data shown represents 
the change in RANKL mRNA expression at 48 hrs by qPCR. Each data point represents 
the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one primary 




































































RANKL HCO IL-6 w/wo TS
Levels are so low or not present therefore not 





3.4.2.3 Expression of OPG mRNA 
The hCOs expressed high levels of OPG. Pairwise comparison identified a significant 
difference between the untreated cells with and without TS (p=0.028). When cultured in 
the presence of an increasing IL-17 dose, a statistically significant decrease in OPG 
expression was identified (p=0.020*, F=4.1). Pairwise comparison identified this 
decrease between 0 ng/mL and 75 ng/mL IL-17 (p=0.039) (Figure 3.16A). OPG 
expression showed a significant difference with the presence TS in untreated controls 
compared to absence of TS (3.8-fold) (Figure 3.16A). However, this finding was not 
confirmed in the IL-6 experiment and additional biological replicates are required (Figure 
3.16B).  
 
When cultured in the presence of an increasing dose of IL-6, no difference in the 




Figure 3.16: Expression of OPG mRNA by hCOs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. (A) addition of IL-17, (B) addition of IL-6. Data shown represents 
the change in OPG mRNA expression at 48 hrs by qPCR. Each data point represents the 
mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one primary hCO 









































































3.4.2.4 Expression of ALP mRNA  
High levels of ALP were detected. When hCOs were cultured with TS, a statistically 
significant increase in ALP was evident in comparison to untreated cells without TS (25-
fold, p=0.034*) (Figure 3.17A). A significant decrease in the expression level of ALP 
was found with an increasing dose of IL-17 in the presence of TS (p=0.024*, F=3.92). 
Pairwise comparison identified this decrease to be significant between 0 ng/mL with TS 
and 75 ng/mL with TS (11-fold, p=0.045*) and approached significant for 0 ng/mL and 
50 ng/mL (p=0.067).  
 
When hCOs were cultured in the presence of an increasing dose of IL-6, no significant 
difference was found in the presence or absence of TS (Figure 3.17B).  
 
 
Figure 3.17: Expression of ALP mRNA by hCOs in monoculture 
IL-17 or IL-6 was added to wells at 0, 50 or 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. (A) addition of IL-17, (B) addition of IL-6. Data shown represents 
the change in ALP mRNA expression at 48 hrs by qPCR. Each data point represents the 
mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one primary hCO 









































































3.4.3 hPDLC and hCO mRNA expression levels following exposure to IL-6 and/or 
IL-17 when cultured as co-cultures. 
 
A co-culture experimental set up was completed with hPDLCs seeded in the wells of a 
24-well plate and with the hCOs seeded in the transwell inserts. An additional 




3.4.3.1 Expression of RANK mRNA  
When hPDLC were cultured without TS, an increasing trend in the expression of RANK 
was identified in the presence of 75 ng/mL IL-17 in comparison to the control of 0 ng/mL, 
however this was not significant (p=0.446, F=1.0) (Figure 3.18A). Despite an increase 
in expression of RANK with and without TS in the presence of IL-17 and IL-6, there was 
no significant additive effect when hPDLC were cultured with both IL-17 and IL-6 as 
opposed to separately. 
 
When hCOs were cultured with TS in the presence of 75 ng/mLIL-6, a statistically 
significant increase in the expression levels of RANK was identified (10-fold, 
p=<0.0001***) compared to the untreated cells with TS (Figure 3.18B). When cultured 
in the presence of both IL-6 and IL-17, there was a statistically significant decrease 
compared to IL-6 alone (p=<0.0001***). Therefore, IL-6 appears to have a greater effect 
on hCOs alone than when IL-17 is present. When TS was not present in culture media, 
there was a statistically significant decrease in the expression level of RANK in the 
presence of 75 ng/mL IL-17 (p=0.003**), IL-6 (p=0.047*) and 75 ng/mL of both IL-17 
and IL-6 (p=0.008**) compared to untreated cells. The effect of TS was not significant 
between untreated cell groups, but higher levels of RANK expression were found in the 
presence of TS for all experimental groups, with a significant increase when cultured in 







Figure 3.18: Co-culture RANK mRNA expression with and without TS, IL-17 
and/or IL-6 at 48 hours 
IL-17 and/or IL-6 was added to wells at 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. Data shown represents the change in RANK mRNA expression at 
48 hrs by qPCR. (A) each data point represents the mean 2^-delta Cq value of one 
primary hPDLC line (N=3, T=3) +/- SD, (B) Each data point represents the mean 2^-
delta Cq value (+/- SEM) for one experimental replicate of one primary hCO line (N=1, 
T=3). Limit of detection indicated by broken line. 
 























































































































3.4.3.2 Expression of RANKL mRNA  
A greater expression of RANKL by hPDLC was observed in the presence of TS compared 
to without TS for IL-17 and/or IL-6, however this was not significant (Figure 3.19A). As 
multiple cell lines had very low levels of RANKL mRNA when TS was not present in 
supplemented media, these results should be interpreted with caution. 
 
hCOs cultured with TS showed an increasing trend in expression of RANKL when 
cultured in the presence of IL-17 and/or IL-6, however this increase was not significant 
(Figure 3.19B). The detection of mRNA was more consistent and at higher levels of 
expression for RANKL when hCOs were cultured in the presence of TS as four out of 12 














Figure 3.19: Co-culture RANKL mRNA expression with and without TS, IL-17 
and/or IL-6 at 48 hours 
IL-17 and/or IL-6 was added to wells at 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. Data shown represents the change in RANKL mRNA expression at 
48 hrs by qPCR. (A) each data point represents the mean 2^-delta Cq value of one 
primary hPDLC line (N=3, T=3) +/- SD, (B) Each data point represents the mean 2^-
delta Cq value (+/- SEM) for one experimental replicate of one primary hCO line (N=1, 





















































































































3.4.3.3 Expression of OPG mRNA 
hPDLC and hCO expression levels of OPG mRNA were consistently higher than RANK 
and RANKL for all experimental conditions. No significant difference was identified in 
OPG expression levels by hPDLC when co-cultured in the presence of IL-17 and/or IL-
6 compared to the control of 0 ng/mL (p=0.420, F=1.1) (Figure 3.20A). The addition of 
TS to supplemented media did not significantly alter the expression of OPG, with no 
significant difference between IL-17, IL-6 and IL-17 and IL-6 compared to the control 
of 0 ng/mL plus TS (p=0.487, F=0.9). 
 
The expression levels of OPG by hCOs in co-culture was not as consistent as hPDLCs 
in the presence of IL-17 and/or IL-6 compared to the control groups. No significant 
difference was identified in the expression levels of hCO in the presence of IL-17 and/or 













Figure 3.20: Co-culture OPG mRNA expression with and without TS, IL-17 and/or 
IL-6 at 48 hours 
IL-17 and/or IL-6 was added to wells at 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. Data shown represents the change in OPG mRNA expression at 48 
hrs by qPCR. (A) each data point represents the mean 2^-delta Cq value of one primary 
hPDLC line (N=3, T=3) +/- SD, (B) Each data point represents the mean 2^-delta Cq 
value (+/- SEM) for one experimental replicate of one primary hCO line (N=1, T=3). 















































































































3.4.3.4 Expression of ALP mRNA  
The mRNA expression levels of ALP by hPDLC cultured together with hCOs showed no 
significant difference between the control groups and IL-17 and/or IL-6 (p=0.314, F=1.7) 
(Figure 3.21A). The presence of TS did not affect the level of expression for all 
experimental conditions and control for hPDLC.  
 
In comparison, hCOs expression levels of ALP was significantly affected by both the 
presence of TS and IL-17 and/or IL-6 in supplemented media (Figure 3.21B). The 
presence or absence of TS had an effect on ALP expression by hCOs. A significant 
increase in ALP expression levels was identified between untreated cells with and 
without TS (6.4-fold, p=<0.001***). When TS was not present, there was a significant 
decrease in ALP mRNA expression in the presence of IL-17 (148-fold, p=<0.0001***), 
IL-6 (p=0.001***) and both IL-17 and IL-6 (p=<0.0001***) compared to the untreated 
cells. This decrease in expression levels was also noted, but to a lesser extent, when TS 
was present in supplemented media in the presence of IL-17 (148-fold, p=0.0009***), 
IL-6 (2-fold, p=0.002**) and both IL-17 and IL-6 (413 fold, p=0.001***) compared to 












Figure 3.21: Co-culture ALP mRNA expression with and without TS, IL-17 and/or 
IL-6 at 48 hours 
IL-17 and/or IL-6 was added to wells at 75 ng/mL with TS (light grey) or without TS 
(black), as indicated. Data shown represents the change in ALP mRNA expression at 48 
hrs by qPCR. (A) each data point represents the mean 2^-delta Cq value of one primary 
hPDLC line (N=3, T=3) +/- SD, (B) Each data point represents the mean 2^-delta Cq 
value (+/- SEM) for one experimental replicate of one primary hCO line (N=1, T=3). 



















































































































3.5 Monoculture mRNA expression levels compared to co-culture  
 
3.5.1 Expression of RANK mRNA  
Higher expression levels of hPDLC RANK expression were detected in co-cultures 
compared to monocultures (Figure 3.22). The level of expression was higher for both the 
untreated cells (390-fold) and when cells were cultured in the presence of IL-17 (33-fold) 
or IL-6 (9888-fold). However, this difference in expression level was not statistically 




Figure 3.22: Co- and monoculture RANK mRNA expression by hPDLC with IL-17 
and/or IL-6 
hPDLCs are cultured in wells in the presence of 75 ng/mL of IL-17 or IL-6 in both mono- 
and co-culture, as indicated. Data shown represents the change in RANK mRNA 
expression at 48 hrs by qPCR. In co-culture, each data point represents the 2^-delta Cq 
value (+/- SEM) for one primary hPDLC line (N=3, T=3) expressed as mean +/- SD and 
in monoculture hPDLC data is presented for four different primary cell cultures (N=4; +/-





















































hCO RANK expression levels were the opposite in comparison to hPDLCs. RANK 
expression levels were lower when hCOs were cultured in co-culture with hPDLCs 
compared to in monoculture (Figure 3.23). Pairwise comparison identified a statistically 
significant increase in RANK expression between 75 ng/mL IL-17 in co-culture with TS 




Figure 3.23: Co- and monoculture RANK mRNA expression by hCOs with IL-17 
and/or IL-6 at 48 hours 
In mono- and co-culture, hCOs are cultured in the presence of 75 ng/mL IL-17 and/or 
IL-6 with or without TS, as indicated. Data shown represents the difference in RANK 
mRNA expression at 48 hrs by qPCR between mono- and co-culture. Each data point 
represents the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one 







































































3.6.2 Expression of RANKL mRNA  
 
Levels of RANKL were low when hPDLCs were cultured in co- and monoculture (Figure 
3.24). Levels were often undetectable and no statistically significant difference between 




Figure 3.24: Co- and monoculture RANKL mRNA expression by hPDLC with IL-
17 and/or IL-6 at 48 hours 
hPDLCs are cultured in wells in the presence of 75 ng/mL of IL-17 or IL-6 in both mono- 
and co-culture, as indicated. Data shown represents the change in RANKL mRNA 
expression at 48 hrs by qPCR. In co-culture, each data point represents the 2^-delta Cq 
value (+/- SEM) for one primary hPDLC line (N=3, T=3) expressed as mean +/- SD and 
in monoculture hPDLC data is presented for four different primary cell cultures (N=4; +/-
SD). Limit of detection indicated by broken line.  
 
Expression levels of RANKL were consistently higher for hCOs than hPDLC with fewer 
samples being undetected. A statistically significant difference in the expression levels 






















































F=2.0) (Figure 3.25). Pairwise comparison identified this difference between 75 ng/mL 
IL-17 + TS in monoculture compared to co-culture, with a greater expression of RANKL 




Figure 3.25: Co- and monoculture RANKL mRNA expression by hCOs with IL-17 
and/or IL-6 at 48 hours 
In mono- and co-culture, hCOs are cultured in the presence of 75 ng/mL IL-17 and/or 
IL-6 with or without TS, as indicated. Data shown represents the difference in RANKL 
mRNA expression at 48 hrs by qPCR between mono- and co-culture. Each data point 
represents the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one 








































































3.6.3 Expression of OPG mRNA  
 
OPG expression levels were high for both monoculture and co-culture by hPDLCs 
(Figure 3.26). No statistically significant difference was identified between hPDLCs in 
monoculture or co-culture for control groups or when cultured in the presence of IL-17 




Figure 3.26: Co- and monoculture OPG mRNA expression by hPDLCs with IL-17 
and/or IL-6 at 48 hours 
hPDLCs are cultured in wells in the presence of 75 ng/mL of IL-17 or IL-6 in both mono- 
and co-culture, as indicated. Data shown represents the change in OPG mRNA 
expression at 48 hrs by qPCR. In co-culture, each data point represents the 2^-delta Cq 
value (+/- SEM) for one primary hPDLC line (N=3, T=3) expressed as mean +/- SD and 
in monoculture hPDLC data is presented for four different primary cell cultures (N=4; +/-
SD). Limit of detection indicated by broken line.  
 
Expression levels of OPG by hCOs were also high in both monoculture and co-culture 


















































for OPG (p=<0.0001, F=9.1). Pairwise comparison identified a greater expression of 





Figure 3.27: Co- and monoculture OPG mRNA expression by hCOs with IL-17 
and/or IL-6 at 48 hours 
In mono- and co-culture, hCOs are cultured in the presence of 75 ng/mL IL-17 and/or 
IL-6 with or without TS, as indicated. Data shown represents the difference in OPG 
mRNA expression at 48 hrs by qPCR between mono- and co-culture. Each data point 
represents the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one 





































































3.6.4 Expression of ALP mRNA 
 
ALP expression levels were similar for both monoculture and co-culture (Figure 3.28). 
No statistically significant difference was identified between control groups or when 




Figure 3.28: Co- and monoculture ALP mRNA expression with IL-17 and/or IL-6 
at 48 hours 
hPDLCs are cultured in wells in the presence of 75 ng/mL of IL-17 or IL-6 in both mono- 
and co-culture, as indicated. Data shown represents the change in ALP mRNA 
expression at 48 hrs by qPCR. In co-culture, each data point represents the 2^-delta Cq 
value (+/- SEM) for one primary hPDLC line (N=3, T=3) expressed as mean +/- SD and 
in monoculture hPDLC data is presented for four different primary cell cultures (N=4; +/-
SD). Limit of detection indicated by broken line.  
 
A statistically significant difference in expression levels of ALP by hCOs was identified 
between mono- and co-culture experimental setups (p=<0.0001***, F=4.9) (Figure 3.29). 


















































group in monoculture compared to co-culture when TS was present in supplemented 




Figure 3.29: Co- and monoculture ALP mRNA expression by hCOs with IL-17 
and/or IL-6 at 48 hours 
In mono- and co-culture, hCOs are cultured in the presence of 75 ng/mL IL-17 and/or 
IL-6 with or without TS, as indicated. Data shown represents the difference in ALP 
mRNA expression at 48 hrs by qPCR between mono- and co-culture. Each data point 
represents the mean 2^-delta Cq value (+/- SEM) for one experimental replicate of one 
















































































This thesis forms the basis of a preliminary study designed to better understand the 
effects that inflammatory mediators have on cells involved in OTM. The behaviour of 
cultured hPDLCs and hCOs grown in monoculture and co-culture with and without triple 
supplement (TS) and supplemented with various doses of IL-17 and/or IL-6 was assessed. 
Cell viability was measured at selected intervals over a 72-hr period and gene expression 
of RANK, RANKL, OPG and ALP were investigated at 48 hours. It was found that the 
addition of IL-17 and/or IL-6 had no significant effect on cell viability over 72 hours but 
did affect the expression of genes associated with osteogenesis. This may play a role in 
stimulation of bone remodelling associated with OTM. 
 
Significance of research  
 
Longer orthodontic treatment time is associated with many risks. These include increased 
root resorption, increased enamel demineralisation, periodontal disease, decreased 
compliance, satisfaction, stress and quality of life. While a shorter treatment is more 
beneficial for both the practitioner and patient, there are limits to the force load a tooth 
can withstand before any damage occurs. This must be well understood by clinicians. 
The increased focus on the biological basis of tooth movement provides a more 
comprehensive understanding of orthodontics. Future design of orthodontic devices and 
use of therapeutic adjuncts will result in safer and potentially more accelerated tooth 
movement, but only once cellular changes and the influence of inflammatory mediators 
during OTM are better understood. 
 
Current therapeutic modalities for acceleration of OTM, such as corticotomies, report a 
reduction in treatment time but burden the patient with an additional surgical procedure 
and associated surgical risks (93). Alternative less invasive measures include low level 
laser therapy, vibration and phototherapy. A Cochrane review in 2015 investigated non-
surgical adjunctive interventions for acceleration of tooth movement and identified very 
little clinical research concerning the effectiveness of these interventions (94). Despite 
marketing claims these therapeutic adjuncts accelerate tooth movement, results of the 
current review do not reach statistical or clinical significance (94). Modulation of tooth 
movement may also be to bolster anchorage, or slow tooth movement in an area. The 
potential of biomodulators in orthodontics to enhance or inhibit recruitment, 
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differentiation or activation of cells, such as hPDLCs and hCOs, could accelerate or 
reduce OTM. In order to safely and accurately administer these biomodulators, greater 
knowledge on the cellular mechanisms and influence of inflammatory mediators 
underlying bone remodelling and OTM is required. This study aimed to increase our 
knowledge on the underlying biological mechanisms and inflammatory mediators, IL-17 
and IL-6, involved in bone remodelling during OTM. This study has emphasized the 
importance of cellular communication and how this can affect a cell’s activity in terms 
of gene expression. Building on current literature, these results help science progress 
towards identifying future immunological modulators of tooth movement. These 
interventions have the potential to improve clinical practice and patient outcomes.  
 
Bone remodelling during OTM  
 
Bone homeostasis is maintained through the process of bony remodelling. This is a 
lifelong process which is achieved via a finely regulated balance between bone resorption 
and formation (95, 96). Two key cells in bone formation and resorption, osteoblasts and 
osteoclasts, are regulated by many local factors. These factors include cytokines, such as 
IL-6 and IL-17, in the bone microenvironment. Both orthodontic and orthopaedic theory 
involve the remodelling of bone and both require a thorough understanding of bone 
biology. However, orthodontic bone remodelling is slightly more complicated and the 
orthodontist must understand the relationship between mechanical stress, various cell 
types involved and the changes that occur in the PDL and surrounding alveolar bone 
during OTM. 
 
A part of this understanding, is the influence of osteogenic genes, such as ALP, on bone 
remodelling. Bone ALP is a major regulator of bone mineralization. It hydrolyses 
inorganic pyrophosphate which is a naturally occurring inhibitor of mineralization. This 
present study showed a significant dose effect of IL-17 on ALP mRNA levels, in 
particular by hCOs in mono- and co-culture. This would impact bone remodelling during 
OTM. Further investigation into whether this gene expression correlates into protein 




The main pathway for bone remodelling underlying OTM is the RANKL–RANK-OPG 
interaction. Alongside hCOs and osteoclast cells, hPDLCs are vital in the response to 
tension and pressure forces delivered during orthodontic treatment and thus OTM. It has 
been suggested that hPDLCs are the first cells to initiate a molecular response to 
orthodontic forces by producing osteoclastogenesis promotors such as PgE2 and RANKL 
in response to pressure forces, and OPG and Runx2 in response to tension forces (57, 
97). RANKL is also expressed by other mesenchymal cells, such as hCOs, and its 
expression may be upregulated by PGE2, vitamin D3, PTH, ILs-1,6,8,11,17,32 and 
TNFα (98). The binding of RANK-RANKL leads to an intracellular cascade, culminating 
in osteoclast related gene expression. hCOs producing RANKL can also induce 
osteoclast differentiation (99). Previous research clearly demonstrates that orthodontic 
force application triggers inflammatory cellular and molecular pathways. However, the 
exact biological factors and processes, their sequence and timing are still unclear. 
 
In vitro cell culture; the strengths and weaknesses of primary cell culture 
 
Primary cells are those taken directly from the source in an unmodified state (100, 101). 
This means that they are physiologically similar to the donor site, making them ideal for 
in vitro experimentation (100). Indeed, Lin et al., (2014) and Shi et al., (2019) have 
previously used hPDLCs to investigate biological mechanisms of OTM (19, 29). 
However, there is often variability in primary human cells due to their heterogenous 
genetic nature, meaning multiple biological replicates need to be obtained to determine 
statistical and biological significance.  
 
This study aimed to further understand orthodontic bone remodelling by measuring the 
effect of IL-17 and IL-6 on hPDLCs and hCOs. Previously, Kim et al., (2014) and Wang 
et al., (2020) used murine calvarial osteoblasts to investigate IL-17 effects on RANKL 
and OPG expression. Immortalised periodontal ligament cells were also used by Kanzaki 
et al., (2019) to investigate OPG expression following compressive and tensive forces 
(60, 102, 103). Therefore, we aimed to build on current literature by using primary hCOs 
and hPDLCs. The use of a primary cell line in this study also enabled experiments on 
human tissues which otherwise could not otherwise have been done in vivo and provided 
more relevant results to what is occurring in the PDL space during OTM. Donor cells 
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were harvested from five people. Inclusion criteria was limited to males, aged 12-18 
years who were medically fit and well and were having extraction of healthy teeth. This 
criteria reduced known variability of genetically heterogenous human samples. Cell 
samples were taken and using methods by Sommerman et al., (1988) and stored frozen 
before use (91). Freezing cells may affect cell behaviour, however this risk is necessary 
in order to conduct the following experiments in adequate time. Therefore, using primary 
cell lines avoids the manipulation associated with immortalised cell lines, meaning they 
are most translatable as an in vitro model.   
 
There are several advantages to the use of primary cells in vitro. Firstly, animal models 
are beneficial when investigating pharmokinetic studies or understanding whole body 
effects of treatments, but they also have physiological differences to humans and 
therefore do not translate well to the in vivo state. Secondly, there are several advantages 
to using a primary cell line over a continuous cell line. Continuous cell lines are 
immortalized, i.e. they have the ability to proliferate indefinitely compared to primary 
cell lines which may have a limited growth potential and eventually senesce and die (101). 
However, as continuous cell lines are genetically modified or transformed, the 
physiological properties of the cells can be altered which does not represent the in vivo 
state as accurately as primary cells (104). It is worth noting that the cells used in this 
study were manipulated as they were cultured on plastic in media, which may alter their 
physiological properties from the in vivo state and may also select for a specific cell type. 
In this study, the use of a commercial osteoblast cell line provided homogeneity and 
ensured the maintenance of the osteoblastic phenotype over a number of generations. 
Sourcing hCOs from a commercial rather than patient source was also easier to confirm 
phenotype and isolation of hCOs only. Continuous culture and passaging, however, can 
still result in a drift towards an undifferentiated cell phenotype (105). Therefore, it is 
recommended that cells of a low passage number are employed for any subsequent 
experiments (105, 106). The disadvantages presented for both animal models and the use 
of a continuous cell line resulted in this study being designed using primary cell lines in 
vitro and cells at passage 3-7 were used for all experiments for both hPDLCs and hCOs 




The results obtained from using primary cells in this study will build on current 
knowledge and provide more relevant information on what is occurring in the PDL 
during OTM.   
 
The dose response of IL-17 and IL-6 on hCO and hPDLC viability  
 
PrestoblueTM is a commonly used assay to determine viability of cells and has been 
utilised to illustrate the dose-response of IL-17 and IL-6 on hCOs and hPDLCs over 72 
hours in this present study. Incubation time for all viability assay experiments was 
standardised at two hours for consistency, which allowed for direct comparison between 
groups. The dose-response of IL-17 on hPDLC viability has previously been investigated 
over 24 and 96 hours using an MTT assay (29, 107). No concentration between 1-100 
ng/mL IL-17 was identified to significantly affect cell viability by Lin et al., (2014) (29). 
However, Đorđević et al., (2016) identified reduced proliferation by 10% at 24 hrs but 
no changes after 48, 72 and 96 hours compared to untreated controls (107). To our 
knowledge, no dose-response experimentation has been completed in a co-culture setup 
with hPDLCs and hCOs or monoculture of hCOs when cultured in the presence of IL-6. 
In this present study, viability assays were conducted over 72 hours for four biological 
replicates of hPDLCs and one hCO cell line. Preliminary results from this study indicated 
that addition of IL17 and/or IL-6 at 0-75ng/mL was not toxic to cells. Cellular viability 
was also unaffected by this dose range of IL-6 or IL-17 over 72 hours in both mono- and 
co-culture of hCO and hPDLCs. Background fluorescence of the media only was 
determined at each timepoint. This is due to the interaction between the resazurin dye 
and cell culture media even in the absence of cells (81). These background readings were 
consistent for all experiments. Future studies may seek to understand the maximum 
tolerated dose of these cytokines on hPDLCs and hCOs to determine whether higher 
concentrations have greater effects on viability. As force may be applied to a tooth for 
greater than 72 hours, and therefore a longer period of an inflammatory response, it 
would be worthwhile monitoring cell viability and assessing osteogenic gene expression 
over a longer time period. Cells may need to be plated at a lower density to allow this in 
order to prevent overcrowding of the well. This would enable a better understanding of 




The effect of triple supplement on hCO and hPDLC viability and gene expression   
 
During the 1970–80s, much effort went into understanding the mechanisms regulating 
the differentiation of mesenchymal stem cells (MSCs) into specialized lineages using 
cultured bone marrow stromal cells and cells isolated from foetal rat calvaria (108-110). 
These investigations established the ability of dexamethasone, ascorbic acid, and β-
glycerophosphate (triple supplement) to promote osteoblast differentiation and 
mineralized bone nodule formation in vitro, thereby providing the methodology for the 
first reports on the directed commitment of human embryonic stem cells to the osteoblast 
lineage (111, 112). From previous research, TS appears to impact cell differentiation, 
mineralisation and cell viability (113, 114). Therefore, we aim to build on this current 
literature by investigating the effect IL-17 and IL-6 have on hCOs and hPDLCs viability 
and osteogenic gene expression with and without TS.   
 
In this present study, the effect of TS on the viability of hCO in monoculture over 72 
hours and hPDLCs and hCOs in co-culture over 48 hours was investigated. The 
importance of TS in culture media for hCO function, including induction of 
mineralisation and nodule formation has previously been investigated by Itskovich et al., 
(2021) (40). When TS was present, more intense staining of calcium-rich areas with 
Alizarin Red was identified and greater ALP activity was noted at 21 days compared to 
cells cultured without TS (40). The present findings indicate that TS had a greater effect 
on hCOs than hPDLC viability in co-culture. Co-culture of hPDLCs and monoculture of 
hCOs showed no significant difference in viability in the presence or absence of TS. 
However, hCO viability did show an increasing trend and further biological replicates 
are required to increase the accuracy of the current findings and generalisability to the 
population. In co-culture, TS was shown not to have an effect in isolation, but when 
combined with IL-17 alone or IL-17 plus IL-6, a significant increase in cell viability of 
hCOs is evident. It is evident that TS is required for hCO function and has a greater effect 
on hCOs than hPDLCs. Further experimentation of hPDLCs in monoculture is required 





The effect of TS on osteogenic gene expression by hCO and hPDLCs was also 
investigated. As TS has been shown to alter cellular activity, such as promotion of hCO 
differentiation and induction of mineralisation, it was hypothesized that it would impact 
cell gene expression. This was confirmed with the addition of TS to hCO baseline 
monocultures resulting in significantly increased OPG and ALP mRNA expression 
compared to the negative control (3.8-fold; p=0.020 and 25-fold; p=0.024, respectively). 
The expression of OPG and ALP by hCO in monoculture significantly decreased and 
RANK expression increased in a dose-dependent manner when in the presence of IL-17 
and TS. These results were also identified in hCO co-culture, with the addition of IL-6 
also significantly increasing the expression of RANK and decreasing the expression of 
ALP. It is clear that the presence of TS in culture medium is required for more accurate 
detection of hCO activity, such as gene expression, in in vitro experiments to be 
comparable to the in vivo envirmonment.  
 
hPDLCs are commonly cultured with Dulbecco’s modified Eagle’s medium, however 
several studies have investigated altering the formulation of culture medium to provide 
optimal culture conditions for hPDLCs (115, 116). Comparison of three in vitro medium 
formulations to determine the optimum culture conditions for long-term expansion of 
periodontal ligament stem cells has been investigated (115). Overall, their results 
indicated that the enriched Ham’s F12 medium formulation (media supplemented with 
10% FBS, heparin 0.5 U/ml, epidermal growth factor (EGF) 50 ng/ml, fibroblast growth 
factor (FGF) 25 ng/ml, and bovine serum albumin (BSA) 1%) was a suitable protocol for 
the expansion and preservation of osteogenic potential of hPDLCs. When TS was also 
added to enriched Ham’s F12 medium, there was promotion of ALP activity, however 
no calcium deposits were detected (115). This study investigated the different media 
formulations on cells derived from one patient only, which allowed for results to be 
determined exclusively due to medium formulations, however further biological 
replicates are required for generalizability to the population. The potential merits of TS 
and bone morphologenetic protein (BMP-2 and BMP-6) on osteogenic differentiation of 
hPDLCs have also been previously investigated (116). hPDLC ALP activity increased 
when TS alone, or in combination with BMP-2 or BMP-6, was present in supplemented 
media. In vitro mineralisaton was also shown to be induced over 21 days of cell culture 
when in the presence of TS alone (116). These findings suggest that TS has the ability to 
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enhance osteogenic differentiation of hPDLCs. In this present study, the effect of TS on 
hPDLC gene expression was not as significant as with hCOs. Promotion of RANK 
expression by hPDLC in the presence of TS was identified, but no effect on RANKL, 
OPG or ALP was clear. It is clear that TS has the ability to impact osteogenic gene 
expression in hCOs and also in hPDLCs to a smaller extent (116). Due to the hCOs 
having an increased cell viability and gene expression in co-culture with TS present, this 
could have influenced the results from hPDLC in co-culture. Therefore, it would be 
worthwhile building on current literature to identify the effects of TS on gene expression 
in hPDLCs in monoculture for comparison. 
 
It is evident that TS is required in culture media to ensure hCOs behave as close as 
possible to the phenotype of in vivo state. While further investigation into the effects on 
hPDLCs alone is required, there is evidence to suggest that a co-culture in vitro model 
with TS present in culture media will best represent the cellular environment in the PDL 
space during OTM.  
 
The effect of IL-17 and IL-6 on gene expression by hPDLCs and hCOs in 
monoculture  
 
During OTM, inflammatory mediators are present at the pressure surface of the tooth 
root. These mediators, including IL-17 and IL-6, act on cells vital for bone remodelling 
and subsequent tooth movement. The aim of this study was to enhance our understanding 
of the cellular biology underlying bone remodelling during OTM. In the late 1990’s, 
various cytokines were identified as the essential components of a signalling system that 
are required for bone remodelling, known as the RANK, RANKL and OPG triad (43, 
44). These key components to bone remodelling were investigated in this thesis to 
determine the effects of IL-17 and IL-6 on hPDLC and hCOs. 
 
It has been well documented that hPDLCs have the capability of reducing bone resorption 
through high expression of OPG in healthy periodontal tissue (29, 117). Various stimuli, 
including orthodontic force and osteolytic cytokines, have the potential to alter the ratio 
of RANKL and OPG in hPDLCs (8, 28, 29). Adding to the body of literature, this study 
investigated the dose-response of IL-17 and IL-6 on osteogenic gene expression by 
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hPDLCs and hCOs. We hypothesized that placing force on a tooth would stimulate an 
inflammatory like reaction at the pressure surface of the tooth and an increase in the 
expression of RANK and RANKL as well as a decrease in OPG and ALP expression due 
to an increase in concentration of IL-17 and/or IL-6. Analysis in monoculture allowed 
for a better understanding of hPDLCs and hCOs alone and could later be used for a 
comparison to establish the effects of co-culture on gene expression.  
 
Gene expression analysis is critical for understanding how IL-17 and IL-6 directly 
influence cell functionality. Previous research by Lin et al., (2014) identified the 
application of 50 ng/mL IL-17 promoted RANK and RANKL expression by hPDLCs 
compared to untreated controls at 24 hours (29). Subsequently, Lin et al., (2014) 
investigated a time-dependent response of hPDLC to 50 ng/mL IL-17 and found that 
mRNA of RANKL was enhanced in a time-dependent manner whereas mRNA of OPG 
was decreased over 48 hours. Although not clear in the paper, a limitation of the study 
by Lin et al., (2014) was that it appears that only one primary cell line was used and 
therefore their results should be interpreted with caution. Two primary hPDLC lines were 
utilised by Shibata et al., (2014) to investigate (10 ng/mL) IL-17 and (0-25 ng/mL) IL-6 
on mRNA expression of MMP-1 over 72 hrs (28). They identified that MMP-1 
expression increased in a time-dependent fashion after 24 hrs, and significantly after 48-
72 hrs of stimulation with IL-17. Improving the quality of evidence available with 
additional biological replicates (N=4), this study identified a dose-dependent response of 
IL-6 promoting RANK and RANKL expression by hPDLCs at 48 hours. This dose-
response was also noted with IL-17, however it was not significant. No difference was 
observed in OPG or ALP expression by hPDLCs when in the presence of IL-6, but an 
increase in ALP expression was noted in the presence of IL-17. Although no change in 
expression of OPG was detected, it would be worthwhile determining if the high 
expression level of OPG detected in all experimental groups correlates to an increase in 
protein production of OPG by the cell. The current findings have strengthened the 
available evidence that inflammatory mediators can influence osteogenic gene 
expression. Future studies may seek to understand the maximum tolerated dose of these 
cytokines on hPDLCs and hCOs to determine whether higher concentrations have greater 




The known effects of IL-17 and IL-6 on osteoblasts is limited. Increased ALP activities, 
have been observed in primary osteoblasts treated with IL-17 or IL-17 in combination 
with IFN-g (78). Promotion of expression of genes ALP, Runx2, osteocalcin, OPG and 
RANKL were also identified when primary osteoblasts were exposed to IL-17 (78). This 
studies’ findings of hCO in monoculture identified the presence of IL-17 to be consistent 
with what has been reported in the literature and what is expected with OTM on 
osteogenic gene expression. A dose-response of IL-17 in hCOs mRNA expression was 
shown with promotion of RANK and downregulation of OPG and ALP. This response 
was present when in the presence of TS. A significant difference in gene expression was 
identified between untreated controls with and without TS, emphasizing the impact of 
TS on hCOs activity. In disagreement with previous research, but in agreement with our 
findings, Zhang et al., (2017) identified a downregulated ALP activity and ALP 
concentration of primary osteoblasts by IL-17 in a dose-dependent manner (79). The 
addition of IL-6 alone, and in the presence of TS did not affect expression of RANK, 
OPG or ALP. An increase in RANKL expression when cultured in the presence of IL-6 
+ TS at 48 hours by hCOs was identified. It would be beneficial to determine whether 
the gene expression findings from our study correlate to changes in protein expression 
by hCOs, whether these proteins are biologically active and if this leads to bone 
remodelling.  
 
IL-6 has been considered as an osteolytic factor involved in periodontal disease. However, 
the effect of IL-6 during OTM on hPDLCs is not clear. The effects of IL-6 and its soluble 
receptor (sIL-6R) have on osteoblastic differentiation of hPDLCs have previously been 
investigated (118). Investigation of whether IL-6/sIL-6R could induce osteoblast-
specific transcription factor Runx2 gene expression in hPDLCs has also been conducted 
(118). Iwasaki et al., (2008) identified that when hPDLCs were stimulated with either 
IL-6 or sIL-6R alone, Runx2 expression was not changed. However, when ascorbic acid 
was present in supplemented media, an increase in Runx2 expression was identified (118). 
In this study, no dose-response of IL-6 on hPDLC expression of RANK, OPG or ALP 
over 48 hours was identified. However, IL-6 did lead to an increase in RANKL expression 
in a dose-dependent manner. It would be worthwhile repeating our gene assay analysis 
to include Runx2 at 48 hours but also increase our timepoint and range of concentrations 
of IL-6 for hPDLC and hCOs in mono- and co-culture. This would build on current 
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literature and give us a greater understanding of the effects of IL-6 over a longer time 
period during OTM. 
 
Inflammatory mediators present during OTM act on cells vital for bone remodelling and 
subsequent tooth movement. It is clear that osteogenic gene expression by hPDLCs and 
hCOs is affected by IL-17 and IL-6, however further studies are required to determine 
the cell signalling pathways and subsequent protein translation that occurs.  
 
The effect of IL-17 and IL-6 on gene expression by hPDLC and hCOs in co-culture  
 
Intercellular communication allows cells to work together to perform important bodily 
processes that are necessary for survival. This is evident through the action of 
extracellular signalling proteins, such as interleukin-6 (IL-6) and interleukin-17 (IL-17). 
They may act in an autocrine or paracrine fashion and can target nearby cells to provide 
cell-cell communication. This communication can affect bone metabolism and thereby, 
OTM. It is reasonable to expect periodontal, osteoclast and osteoblast cells to 
communicate throughout OTM. Therefore, the use of a co-culture in vitro model in this 
study allowed for a greater representation of the in vivo environment.  
 
It has been reported that direct cell-cell contact between osteoclast precursors and 
hPDLCs could significantly induce a synergistically increased expression of 
osteoblastogenesis-related genes. Ultimately, this would promote the formation of 
osteoclasts, suggesting that hPDLCs can support osteoclast formation via production of 
RANK and RANKL and inhibition of OPG production (8). Current literature indicates that 
hPDLCs can serve as osteoblast-supporting cells. Investigation of the relationship 
between the immune response and inflammatory alveolar bone loss is required due to the 
inflammatory like response in the PDL following the application of orthodontic force. 
The hypothesis of this study was that cellular communication between hCOs and 
hPDLCs would lead to promotion of RANK and RANKL and a downregulation of OPG 
and ALP expression when in the presence of IL-6 and/or IL-17. This was confirmed for 
hPDLCs. When cultured together, a greater expression of RANK mRNA was observed 
by hPDLC compared to monoculture for untreated cells as well as experimental groups. 
This could be attributed to the effect of communication between the hCOs as hPDLC 
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expression of RANK was increased in unaffected cells as well as cells cultured in the 
presence of TS, IL-17 and/or IL-6. However, levels of RANKL, OPG and ALP were 
unaffected by hPDLCs in co-culture compared to mono-culture. In accordance with the 
literature, expression levels of RANKL were increased and OPG and ALP decreased in 
co-culture of hCOs compared to mono-culture. Interestingly, hCO mRNA expression 
levels of RANK were higher in mono- compared to co-culture, although it would be 
worthwhile repeating this with a greater number of biological replicates to gain further 
precision of these results. In the presence of IL-17, hCO RANKL expression was 
significantly increased in co- compared to monoculture. This highlights the effect 
communication with hPDLCs has on gene expression by hCO cells.  
 
It is clear that communication between cells involved in bony remodelling is present and 
vital at multiple steps in this process. This also demonstrates the importance of utilising 
an in vitro model which more accurately demonstrates the in vivo environment of what 









Last century, Sandstedt published the first experimental investigation of OTM. Since 
1905, in vitro and in vivo investigation of OTM has improved our knowledge on the 
sequence of events at a tissue and cellular level. This current study has focussed on 
increasing our knowledge of two cells vital to bone remodelling during OTM. The 
technique of qPCR has allowed us to identify the effects of two key cytokines involved 
in the inflammatory response on osteogenic gene expression by hPDLCs and hCOs. The 
effects of IL-17 and IL-6 on osteogenic gene expression at 48 hours have been shown, 
however this does not necessarily mean a change in protein translation or that the protein 
is biologically active. Therefore, further experimentation is required to determine 
whether the changes in gene expression identified do indeed correlate to a change in 
protein translation by hPDLC and hCOs through the use of ELISA assays. This change 
in protein translation will ultimately affect cell function and bone remodelling during 
OTM.  
 
Recommendations for future research include additional experiments in order to better 
understand the dose and time relationship IL-17 and IL-6 have on hCO and hPDLCs. In 
order to gain a better understanding of what would occur in the PDL space during OTM 
and prolonged exposure to IL-17 and/or IL-6, repetition of the viability assays over a 
longer period of time (greater than 72 hours) is required. Increasing the number of 
biological replicates for hCO is also required for both co- and monoculture experiments. 
Averaging across biological replicates would increase the generalisability to the 
population and greater technical replicates will improve the precision of viability assays 
and gene expression measurements and allow smaller changes to be detected. Repeating 
the co-culture experiments with a change in cell position is required with hCOs in the 
well and hPDLCs in the inserts using identical cell densities as indicated in the above 
experimental methods. This would allow ruling out of any differences in both viability 
and gene expression of the cells due to cell position, however as the media and cell 
densities were the same, we do not anticipate a difference.   
 
There has been significant proliferation of literature on 3-D culture systems over the past 
few decades (40, 119, 120). One advantage of in vitro 3-D culture system over 2D 
monolayers is the ability to model the natural in vivo extracellular matrix (ECM) scaffold. 
Cell interaction with the ECM has an effect on cell morphology, growth, proliferation, 
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function and may also shift the phenotypic expression of already differentiated cell types 
(119). This study aimed to investigate the communication between hCOs and hPDLCs 
with direct contact and was therefore completed in 2D monolayers. We have shown the 
importance of cellular communication in changes to gene expression. Future research 
identifying the effects of IL-17 and IL-6 in a 3D construct could be a suitable next step 
with the ability to apply force to this construct and thus simulate the in vivo environment 
surrounding a tooth during OTM.  
 
Gene assays for hCO and hPDLCs were investigated. There is little information in the 
literature to compare the results of gene assays from hCOs cultured in the presence of 
IL-6. What information there is available, is often from cells sourced from animals (121, 
122). It would be worthwhile increasing the range of concentration of IL-6 and time 
points to determine whether greater effects are identified over a longer period of time or 
with a different concentration. It would also be worthwhile conducting further 
investigations to determine if the change in mRNA expression, or an increase in receptors, 
correlates with a change in protein production of RANK. RANKL, OPG and ALP by 
hCOs. Further research could also include investigation into the expression of the IL-
17R/IL-6R at each time point to further understand the role IL-17/IL-6 plays in bone 
remodelling. This would give us a better understanding of the role that IL-17 and/or IL-
6 have on osteogenic gene expression by hPDLC and hCOs.  
 
This current study has identified the effects of TS on hCOs in mono- and co-culture and 
hPDLC in co-culture. TS was shown to have an effect on hPDLC in co-culture. Given 
the current findings and those of previous research, it would also be worthwhile repeating 
viability and gene assays to determine the effect of TS on hPDLCs in monoculture. 
Establishing whether TS has an impact on the translation of osteogenic proteins by hCOs 
and hPDLCs would also be worthwhile for better understanding of the impact of TS on 
cellular activity.  
 
The proteins, OPG, RANK and RANKL, are expressed in the gingival crevicular fluid 
within 24 hours post application of orthodontic force (25). Promising orthodontic 
research by Dunn et al., (2007) and Sydorak et al., (2019) on administration of OPG in 
animal models has identified inhibitory movement effects on desired teeth, thus 
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bolstering anchorage (26, 27). In areas where the clinician desires additional anchorage 
to prevent tooth movement, it would be worthwhile detecting the level of IL-17 and IL-
6 as well as the levels of OPG, RANK and RANKL. This is due to the influence IL-17 
has shown from our study and previous research on the gene expression of OPG, RANK 
and RANKL as well as ALP at 48 hours by hPDLC and hCOs. Issues from the above 
animal studies included unwanted effects on adjacent teeth following administration of 
OPG and detection of OPG in the systemic circulation (26, 27). Determination of the 
effects of IL-17 and IL-6 on osteogenic protein translation by hPDLC and hCOs is 
required. This will provide orthodontists with a greater knowledge of what is happening 
at a cellular level during OTM. Following this confirmation, identifying the 
concentration of IL-17 and IL-6 in the gingival crevicular fluid could lead to 
individualizing the dose of OPG delivered or potentially use them as biomarkers for 
improvement in diagnosis and clinical outcomes.   
 
Two cytokines, IL-17 and IL-6, were investigated in this current study. It is believed that 
hCO and osteoclast differentiation and proliferation are affected through the JAK/STAT 
signalling pathway. Activation of this pathway occurs when hCO are exposed to IL-17 
(60). Previous research has also revealed the need for activations of JAK2-STAT3 in the 
expression of RANKL of mesenchymal stem cells, including hCOs and osteocytes by 
IL-6 and IL-17 (60, 123). In brief, extracellular signalling molecules, including the 
cytokines IL-6 and IL-17, interact with the corresponding transmembrane receptor, thus 
stimulating the pathway. Following binding to the receptor, signal transduction occurs 
resulting in activated STATs which dimerize and enter the nucleus. Here, the dimerized 
STATs regulate the transcription of various genes that regulate cell proliferation and 
differentiation (124). IL-6 and IL-17 play an important role in promoting differentiation 
of hCOs toward a more mature phenotype. This action is mediated primarily through the 
JAK/STAT pathway (60, 125). Therefore, activation of JAK/STAT provides a clear 
signalling pathway to investigate downstream transcriptional responses in specific target 
genes to extracellular signals, such as IL-6 and IL-17 in future research on primary 
human cells. 
 
In summary, while the ‘pressure-tension’ theory of OTM provides insight into how teeth 
move during treatment, it has become evident that it is an oversimplified concept. This 
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study has begun to bridge the gap of knowledge on cellular mechanisms underlying bone 
remodelling during OTM. Further investigation is required in this field but it is an 
exciting direction for orthodontists striving to understand the implications of the immune 
response, cellular changes and the resulting bone remodelling during tooth movement. 
Through the use of findings from in vitro and in vivo research, we will be able to progress 
towards providing a more individualised approach to treatment focussed on biology that 
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Wednesday, 19 June 2019 
Dr Fiona Firth 
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Tēnā Koe Dr Fiona Firth, 
Modulation of osteoblasts and periodontal ligament cells by IL-17 and IL-6 
The Ngāi Tahu Research Consultation Committee (the Committee) met on Tuesday, 11 June 
2019 to discuss your research proposition. 
By way of introduction, this response from the Committee is provided as part of the 
Memorandum of Understanding between Te Rūnanga o Ngāi Tahu and the University. In the 
statement of principles of the memorandum it states ″Ngāi Tahu acknowledges that the 
consultation process outline in this policy provides no power of veto by Ngāi Tahu to research 
undertaken at the University of Otago″. As such, this response is not ″approval″ or ″mandate″ 
for the research, rather it is a mandated response from a Ngāi Tahu appointed committee. This 
process is part of a number of requirements for researchers to undertake and does not cover 
other issues relating to ethics, including methodology they are separate requirements with 
other committees, for example the Human Ethics Committee, etc. 
Within the context of the Policy for Research Consultation with Māori, the Committee base 
consultation on that defined by Justice McGechan: 
″Consultation does not mean negotiation or agreement. It means: setting out a proposal not 
fully decided upon; adequately informing a party about relevant information upon which the 
proposal is based; listening to what the others have to say with an open mind (in that there is 
room to be persuaded against the proposal); undertaking that task in a genuine and not 
cosmetic manner. Reaching a decision that may or may not alter the original proposal.″ 
The Committee suggests dissemination of the findings to relevant Māori health organisations, 
for example the National Māori Organisation for Dental Health, Oranga Niho. For any 
questions on the research, use or disposal of human samples, or matters relating to consent to 
participate and of a cultural nature could be referred to Professor John Broughton who is 
involved in Māori Dental Health at the University of Otago.  
 
This letter of suggestion, recommendation and advice is current for an 18-month period from 







7.2. Ethical approval  
22 July 2019
Academic Services
Manager, Academic Committees, Mr Gary Witte
H19/099
Dr F Firth
Department of Oral Sciences
Faculty of Dentistry
Dear Dr Firth,
I am writing to let you know that, at its recent meeting, the Ethics Committee considered your
proposal entitled “Modulation of osteoblasts and periodontal ligament cells by IL-17 and
IL-6”.
As a result of that consideration, the current status of your proposal is:- Approved
For your future reference, the Ethics Committee’s reference code for this project is:- H19/099.
The comments and views expressed by the Ethics Committee concerning your proposal are
as follows:-
While approving the application, the Committee would be grateful if you would respond to the
following:
Samples
The Committee commented that you may need more samples if the cultures do not grow. If
additional samples are required, please advise the Committee via a request for amendment
to the study.
Information Sheet
The Committee thought the Participant Information Sheet needed to be more ‘patient friendly’
and asks that it is reworded using lay language.
Consent Form
Please provide an option to allow participants to indicate whether they wish for their sample
to be disposed of with a karakia.
Please provide the Committee with copies of the updated documents, if changes have been
necessary.
The standard conditions of approval for all human research projects reviewed and approved











Manager, Academic Committees, Mr Gary Witte
H19/099
Dr F Firth
Department of Oral Sciences
Faculty of Dentistry
Dear Dr Firth,
I am again writing to you concerning your proposal entitled “Modulation of osteoblasts and
periodontal ligament cells by IL-17 and IL-6”, Ethics Committee reference number
H19/099.
Thank you for your email requesting an amendment to increase participant from three to five
in number. The Committee approves this amendment.
Your proposal continues to be fully approved by the Human Ethics Committee. If the nature,
consent, location, procedures or personnel of your approved application change, please






 c.c. Professor RD  Cannon    Department of Oral Sciences
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Participant information sheet 
 
Study title: Modulation of osteoblasts and periodontal ligament cells by IL-17 
and IL-6  
Principal 
investigator: 
Name: Fiona Firth 
Department of Oral Sciences 
Position: Senior Lecturer in Orthodontics 




03 479 8889 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully. Take time to consider and, if you wish, talk with relatives or friends, before 
deciding whether or not to participate.  
If you decide to participate we thank you.  If you decide not to take part there will 
be no disadvantage to you and we thank you for considering our request.   
 
What is the aim of this research project? 
During orthodontic tooth movement, forces are used to move teeth into the 
desired position.  This force results in changes to the soft tissue and bone 
surrounding the teeth.  In order to generate these changes in the soft and hard 
tissues, and thus move the teeth, the cells surrounding the teeth perform differently 
than when no force is applied to a tooth. Two cell types vital to the process of tooth 
movement are periodontal ligament cells and osteoblasts (bone producing cells).  
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We intend to investigate the response of two cell types: periodontal ligament cells 
and osteoblast cells subjected to cell signalling molecules, in a laboratory. The results 
of this study may have clinical applications in the prevention of root resorption 
(dissolving of the roots, which is possible during orthodontic treatment), or the 
acceleration of tooth movement (resulting in shorter treatment time with braces 
on). 
 
Who is funding this project? 
Funding has been sought from the New Zealand Dental Research Foundation. 
 
Who are we seeking to participate in the project? 
Potential participants will be undergoing orthodontic treatment within the Discipline 
of Orthodontics at the Faculty of Dentistry, University of Otago. Participants will 
have consented to orthodontic treatment plans involving extraction of one or more 
premolar tooth/teeth. For this study, the teeth must be free of decay or gum disease 
so that these factors do not influence the results of the study. 
 
If you participate, what will you be asked to do? 
We will ask that participants donate one of their extracted teeth. The tooth will be 
processed for the study immediately following the appointment for its removal. No 
additional appointments will be required outside of the extraction appointments that 
would be normally scheduled. 
No aspect of orthodontic clinical care will be affected by your agreement or refusal 
to participate in this research. Participation is entirely voluntary. 
 
Is there any risk of discomfort or harm from 
participation? 
Participating in this study has no additional risk of discomfort or harm beyond those 
of orthodontic treatment in general, which will have been discussed with you. 
 
What specimens, data or information will be collected, 
and how will they be used?  
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Premolar teeth will be collected, and stored securely in the Molecular Biosciences 
Laboratory located within the Biochemistry building at the University of Otago. The 
teeth will be stored for the duration of the study. Following this time, we may 
discard the teeth (using a dental waste system) with a Karakia (Māori Prayer), or 
return them to you as you wish.  
Laboratory techniques will be used to grow cultures of PDL cells. It is these cultures 
of cells that will be experimented on. These cells will be stored for the duration of 
the study before being discarded. 
 
What about anonymity and confidentiality? 
Anonymity will be employed during the research procedure, so that confidentiality is 
achieved. Codes rather than names will be used to label the teeth and cell cultures, 
and reported results will be anonymous. 
 
If you agree to participate, can you withdraw later? 
You may withdraw from participation in the project at any time and without any 
disadvantage to yourself.  
 
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Name: Marguerite Paterson (DClinDent 
(Orthodontics) student) or Fiona Firth 
(Senior Lecturer in Orthodontics) 
Department of Oral Sciences 
Contact phone number: 
03 479 7068 
 
This study has been approved by the University of Otago Human Ethics Committee 
(Health). If you have any concerns about the ethical conduct of the research you may 
contact the Committee through the Human Ethics Committee Administrator (phone +64 3 
479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be treated in 




7.5. Consent form for participants 
 
 
Modulation of osteoblasts and periodontal 
ligament cells by IL-17 and IL-6  
 
Principal Investigator: Fiona Firth 
 03 479 7068; fiona.firth@otago.ac.nz 
Student Investigator: Marguerite Paterson 
03 479 7068; patma316@student.otago.ac.nz 
 
Consent form for participants  
 
Following signature and return to the research team this form will be stored in a secure place for ten 
years. 
 
Name of participant:………………………………….. 
1. I have read the Information Sheet concerning this study and understand the 
aims of this research project. 
2. I have had sufficient time to talk with other people of my choice about 
participating in the study.   
3. I confirm that I meet the criteria for participation which are explained in the 
Information Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am 
free to withdraw from the project at any time without disadvantage. 
6. I know that as a participant I will donate one of my teeth that will be removed 
for orthodontic treatment. 
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7. I understand the nature and size of the risks of discomfort or harm which are 
explained in the Information Sheet. 
8. I know that when the project is completed all personal identifying information 
will be removed from the paper records and electronic files which represent 
the data from the project.  
9. I understand that the results of the project may be published and be available in 
the University of Otago Library, but I agree that any personal identifying 
information will remain confidential between myself and the researchers during 
the study, and will not appear in any spoken or written report of the study  
10. I know that there is no remuneration offered for this study, and that no 
commercial use will be made of the data.  
11. I understand that the tooth samples will be securely stored at the Faculty of 
Dentistry, University of Otago, and will be either returned to me or will be 
disposed with a Karakia following the research period. 
 
Signature of participant:  Date: 
   
 
Signature of parent/guardian (if 




   
   
If you would like to receive your tooth back following our investigation then please 





If you do not want your tooth back following the investigation, would you like the 
tooth disposed of with a karakia?  
 
Please circle     Yes      or      No 
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7.6. Cell culture medium preparation  
 
Reagents and materials 
• D-MEM with GlutaMAX™ (Thermo Fisher Scientific, Cat no. 10566024)  
• Foetal bovine serum (FBS) (Gibco, Life technologies, Cat no. A3160902)  
• Antibiotic antimycotic 100x; Penicillin, Streptomycin, Amphotericin B 
(Thermo Fisher Scientific, Cat no. 15240096) 
• Gentamycin (Gibco, Life technologies, Cat no. 15710064) 
 
Prepare the supplement culture media (500 mL): 
1. Bring reagents to room temperature.  
2. Remove 57.5 mL from 500 mL D-MEM media bottle and replace with FBS, 
Antibiotic antimycotic (100x) and Gentamicin (Table 1).  
3. Mix well. 
4. Store at 4 ℃. 
 
Table 1: Contents of cell culture medium 






Dulbecco’s Modified Eagle Medium 
(high glucose) 
 
442.5 mL 88.5% 









100 unit/mL Penicillin 
100 µg/mL Streptomycin 
0.25 µg/mL Amphotericin B 





7.7. Triple supplement preparation  
 
Reagents and materials 
• Sterile MQ H2O 
• 2-phospho L-Ascorbic acid (Sigma 49752, soluble in water at 0.3 g / 
10 mL) 
• Dexamethasone (Sigma D2915, soluble in water at 25 mg / mL) 
• β-Glycerophosphate (Sigma G9422, soluble in water at 10 mg / mL) 
Equipment 
• Five-digit balance  
• Vortex mixer 
 
Procedure 
1. Make stock solutions. Weigh out the required amounts (see table below). 
2. Dissolve reagents in H2O and sterile filter using a 0.22 μm filter attached 
to a 10 mL sterile syringe. 
3. Aliquot working stock of dexamethasone, ascorbic acid and β-
glycerophosphate into 1.5 mL microfuge tubes and freeze at -20˚C. 
 
Table 2: Triple supplement reagents 
Reagent  MW  
(g/mol) 
Stock concentration  Volume required for 
50 mL media 
Dexamethasone (for 
growth) 
392.4 10 mM (3.9 mg/ 1 mL)1 
Working stock: 
100 μm (1:100) 
(50 μl/ 5 mL media) 
 
Final: 
Use 50 μl of working 
stock (1:1000) 
10-7 M (0.1 μM) 
2-phopho-L-ascorbic 
acid  
322.05 100 mM (322 mg / 10 mL)1 Final: 
Use 100 μl (1:500) 
2 x 10-4 (0.2 mM) 
β-glycerophosphate  216.04 1 M (2160 / 10 mL)1 Final: 
Use 500 μl (1:100) 
10 x 10-3 (10 mM) 
1 Dissolve in sterile H2O 
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7.8. Cell counting using a haemocytometer  
 
Reagents and materials  
• Filtered 0.4% trypan blue solution (Gibco, life technologies, Cat no. 
15250061) 
• 70% ethanol (Thermo Scientific, Cat no. BP8201500 ) 
• Filter, sterile Eppendorf tubes, pipettes (Gibco, Life technologies) 
 
Equipment  
• Light microscope (EVOS M5000) 
• Neubauer Haemocytometer  
 
Procedure  
1. Clean haemocytometer with 70 % Ethanol. Moisten the shoulders of the 
haemocytometer and affix the coverslip. 
2. Mix cells gently by pipetting up and down. Transfer cells (15 μL) and trypan 
blue (15 μl, 1:1) to a 1.5 mL microfuge tube.  
3. Pipette 15 μL of the resulting solution onto a haemocytometer using capillary 
action with the end of the pipette tip at the edge of the coverslip. Repeat to fill 
the second chamber.  
4. Use 10x magnification to bring the grid lines of the haemocytometer into 
focus. Count the live cells (clear cells with blue halos). Dead cells appear dark 
blue.  
5. Count the cells in each of the four large squares. Each large square is made of 
16 small squares. Calculate average for four large grids. Multiply by 2 to 
adjust for 1:1 dilution with tryphan blue. Total cell count is equivalent to = x 






7.9. Cryopreservation and storage of cells  
Reagents and materials 
• Phosphate buffered saline (PBS) without Ca++ and Mg++ (Gibco, Life 
technologies, Cat no. 10010031)  
• 0.25 % Trypsin/EDTA (Gibco, Life Technologies, Cat No. 25200072) 
• Cryopreservation media; containing 10% dimethyl sulphoxide (DMSO) (Cat 
No. D-2120620; Sigma Aldrich) and 90% FBS  
• Sterile cryovials clearly labelled 
Equipment  
• Centrifuge swinging bucket rotor (Beckman Coulter) 
• Cell freezing Device (Nalgene Labware Mr FrostyTM, Rochester, USA)  
Procedure  
1. When cells have reached 60-80% confluency, they can be frozen until 
required. One T-75 flask at 80% confluency has sufficient cells to be spilt into 
three cryovials.  
2. Make cell freezing/cryo-media and place at 4 ̊C.  
3. Trypsinise the cells as per passaging adherent cells using trypsin. Centrifuge at 
220xg for 5 minutes at 21 ̊C to pellet cells. Remove supernatant.  
4. Add 3 mL of cryo-media to the pelleted cells, pipette up and down to make a 
homogenate suspension. Transfer 1 mL into each 1.5 mL labelled cryovials.  
5. Place the cryovials into cell freezing device, "Mr FrostyTM" (kept at room 
temperature) and place at -80  ̊C to freeze cells at 1  ̊C / minute. Transfer to 








7.10. Thawing cryopreserved cells  
Reagents and materials  
• T-25 Culture flasks  
• Pre-warmed complete culture media (as prepared per Appendix 1)  
Equipment  
• Light microscope (EVOS M5000)  
• Water bath 37  ̊C  
Procedure  
1. Prepare a culture flask containing pre-warmed media, ready to receive the 
cells.  
• Refer to Table 4 for volume of culture flasks 
• For T-25, add 4 mL of pre warmed media 
2. Cryopreserved cells are delicate. Remove vial from liquid nitrogen. 
Immediately thaw the cells in a 37  ̊C water bath and rotate gently until the 
frozen contents have just melted.  
3. Gently tip the contents of the cryovial (1 mL) into the culture flask.  
4. Check for the presence of cells under the microscope. Place flask in 37  ̊C, 5% 
CO2 humidified incubator. Do not disturb so as to allow attachment of the cells 
to the flask surface. At 24 hours, change media to remove residual DMSO and 
unattached cells, then every 3 days until 80% confluency is achieved.  















• Distilled water 
• Complete culture media (as prepared per Appendix 1)  
Procedure 
1. Bring Reagents to room temperature. 
2. Add 1 mL of distilled water to 10 µg IL-17A to create a master mix of 10 µg / 
1 mL (10ng / 1 µL). 
3. Utilise calculations in table 6 to prepare desired concentrations of 0, 25, 50 
and 75 ng / mL for dose experiments for up to 65 wells.  
4. Repeat steps 1-3 to create a master mix of IL-6 and concentrations of 
0,25,50,75 ng / mL for dose experiment.  
 
Table 3: Useful cell culture well information 










12 well plate  380 6.9  0.76-1.14  1 x 105 cells 
24-well plate 190  3.4  0.38-0.57  5 x 104 cells 
 
Table 4: Required volume of supplemental media and volume of interleukin required per desired 










required for 65 
wells (mL) 
Total concentration 
of IL-17A ng / mL 
in 32.5 mL media  
0 ng / mL 65 0.5  32.5  0 
25 ng / mL 65 0.5  32.5  812.5 (81.25 µL) 
50 ng / mL 65 0.5  32.5  1625 (162.5 µL) 
75 ng / mL 65 0.5  32.5  2437.5  (243.75 µL) 
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7.12. PrestoBlueTM cell proliferation staining protocol  
 
Reagents  
• PrestoBlue™ (Invitrogen, Cat No A13261) cell proliferation reagent. 
Supplied as a 10x solution 
 
Equipment  
• Synergy 2 Multi-mode microplate reader (Biotek, USA) Excitation 540/25, 




1. Bring Reagents to room temperature. 
2. Add PrestoBlue™ at a 1:10 ratio to media volume. Include a control well with 
media only to correct for background fluorescence. Place culture plate in 37 
 ̊C, 5% CO2 humidified incubator. 
3. Using a fluorescence microplate reader with filters set at excitation 540/25nm 
and emission 620/40 nm, record fluorescence levels. Cell growth is given 
as a percentage of untreated control (at 100%) at each time point, after 















7.13. RNA sample preparation 
 
Reagents  
• TRIzolTM (Life Technologies, Cat No. 15596-026) 




Lyse hPDLC and HCO cells directly in 24-well plates / inserts.  
1. Transfer supernatant from each well into labelled 2.0 mL collection tubes and 
store at -80˚C until required. 
2. Wash each well with 100 uL PBS.  
3. Add 300 uL TRIzol to each well and 100 uL TRIzol to each insert.  







7.14. RNA purification   
 
Reagents and materials  
• 95-100% Ethanol  
• Direct-zol RNA PreWash concentrate  
• RNA wash buffer concentrate 
• DNase I  
• DNase/RNase-Free water  
 
Reagent preparation  
1. Add 40 mL ethanol (95-100%) to the 160 mL Direct-zolTM RNA Prewash 
concentrate.  
2. Add 48 mL 100% ethanol to the 12 mL RNA Wash Buffer concentrate.  
3. Reconstitute lyophilized DNase I with 275 µL DNase/RNase-free water, mix 
by gentle inversion and store frozen from aliquots.  
 
RNA purification  
1. Add an equal volume ethanol (95-100%) to each sample lysed in TRIzolTM 
(300 µL) and mix thoroughly. 
2. Centrifuge in a Zymo-SpinTM IC column in a collection tube.  
3. Transfer into a new collection tube and discard the flow through.  
4. DNase treatment  
a. Add 400 µL RNA Wash buffer to the column and centrifuge1.  
b. In an RNase-free tube, add 5 µL DNase, 35 µL DNA Digestion Buffer (per 
sample) and mix by gentle inversion. Add the mix direction to the column 
matrix.  
c. Incubate at room temperature (20-30˚C) for 15 minutes.  
5. Add 400 µL Direct-zolTM RNA PreWash to the column and centrifuge. 
Discard the flow-through and repeat this step.  
6. Add 700 µL RNA Wash Buffer to the column and centrifuge to ensure 
complete removal of the wash buffer. Transfer the column carefully into an 
RNase-free tube.  
7. To elute the RNA, add 15 µL of DNase/RNase-Free water directly to the 
column matrix and centrifuge.  
8. The eluted RNA can be used immediately or stored at -20˚C until required.  
1 Centrifuge at 12,000 x g for 60 seconds at room temperature   
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7.15. Viability fluorescent units data  
 
7.15.1 hPDLC in monoculture 
Viability fluorescent units for hPDLCs cultured in the presence of 0, 25, 50 or 75 










IL-6 units IL-17 units 
1 1 0 2 75012 77745 
1 2 0 2 60546 74322 
1 3 0 2 71108 74296 
1 1 25 2 65442 79235 
1 2 25 2 61589 76875 
1 3 25 2 63484 76206 
1 1 50 2 65339 66186 
1 2 50 2 67487 67845 
1 3 50 2 67229 70837 
1 1 75 2 78303 77411 
1 2 75 2 62410 78478 
1 3 75 2 69691 78440 
1 1 0 6 87941 75156 
1 2 0 6 95267 70727 
1 3 0 6 104155 77181 
1 1 25 6 88104 72755 
1 2 25 6 82689 71965 
1 3 25 6 94675 71417 
1 1 50 6 91298 66195 
1 2 50 6 90982 70317 
1 3 50 6 102075 74610 
1 1 75 6 96371 73715 
1 2 75 6 92868 76678 
1 3 75 6 106001 85059 











IL-6 units IL-17 units 
1 2 0 24 176374 86215 
1 3 0 24 153369 84236 
1 1 25 24 150301 75832 
1 2 25 24 184942 78232 
1 3 25 24 170954 86544 
1 1 50 24 162907 82167 
1 2 50 24 172418 82071 
1 3 50 24 170122 87264 
1 1 75 24 149561 94040 
1 2 75 24 168202 96524 
1 3 75 24 156554 101311 
1 1 0 48 214131 103705 
1 2 0 48 210221 100642 
1 3 0 48 218845 98583 
1 1 25 48 227648 107966 
1 2 25 48 230730 104047 
1 3 25 48 220343 100774 
1 1 50 48 222431 105336 
1 2 50 48 220476 104257 
1 3 50 48 225374 97261 
1 1 75 48 235352 115679 
1 2 75 48 234132 113727 
1 3 75 48 236241 104930 
1 1 0 72 264204 89540 
1 2 0 72 252671 92303 
1 3 0 72 228059 97235 
1 1 25 72 243345 93852 
1 2 25 72 253219 100567 
1 3 25 72 259058 99122 
1 1 50 72 239064 97490 











IL-6 units IL-17 units 
1 3 50 72 267194 106584 
1 1 75 72 286131 100400 
1 2 75 72 273486 102748 
1 3 75 72 266561 120282 
2 1 0 2 57755 58065 
2 2 0 2 57908 56510 
2 3 0 2 63622 59402 
2 1 25 2 54971 59343 
2 2 25 2 58810 57043 
2 3 25 2 57672 62392 
2 1 50 2 58760 59884 
2 2 50 2 58440 59072 
2 3 50 2 61477 63020 
2 1 75 2 57686 61373 
2 2 75 2 59695 60798 
2 3 75 2 63652 59609 
2 1 0 6 73403 71311 
2 2 0 6 68314 74316 
2 3 0 6 73292 74984 
2 1 25 6 72127 68340 
2 2 25 6 74462 66828 
2 3 25 6 71272 73844 
2 1 50 6 68608 71997 
2 2 50 6 65477 76632 
2 3 50 6 71956 75046 
2 1 75 6 66924 71771 
2 2 75 6 65922 73020 
2 3 75 6 70872 72729 
2 1 0 24 75922 118206 
2 2 0 24 75823 128623 











IL-6 units IL-17 units 
2 1 25 24 85993 126858 
2 2 25 24 76927 124198 
2 3 25 24 89783 137582 
2 1 50 24 87683 117768 
2 2 50 24 87365 118942 
2 3 50 24 90167 135052 
2 1 75 24 90420 122045 
2 2 75 24 89868 117060 
2 3 75 24 93012 137031 
2 1 0 48 119113 84937 
2 2 0 48 123116 83811 
2 3 0 48 120782 83136 
2 1 25 48 114163 73613 
2 2 25 48 117050 88295 
2 3 25 48 118031 61824 
2 1 50 48 125120 80888 
2 2 50 48 126147 79614 
2 3 50 48 126550 88278 
2 1 75 48 137493 89526 
2 2 75 48 128823 82855 
2 3 75 48 133884 80169 
2 1 0 72 144385 101154 
2 2 0 72 137491 100675 
2 3 0 72 139409 108269 
2 1 25 72 132696 92382 
2 2 25 72 127347 94334 
2 3 25 72 136134 101029 
2 1 50 72 133906 87557 
2 2 50 72 132173 89876 
2 3 50 72 133678 94372 











IL-6 units IL-17 units 
2 2 75 72 145467 99445 
2 3 75 72 133678 102507 
3 1 0 2 62774 88984 
3 2 0 2 57479 88746 
3 3 0 2 59766 87446 
3 1 25 2 60809 86908 
3 2 25 2 57539 88712 
3 3 25 2 63146 85969 
3 1 50 2 65457 81926 
3 2 50 2 57709 81745 
3 3 50 2 60149 83726 
3 1 75 2 57154 88454 
3 2 75 2 54259 87567 
3 3 75 2 56659 87678 
3 1 0 6 79729 81840 
3 2 0 6 80075 83191 
3 3 0 6 73011 82114 
3 1 25 6 75533 77684 
3 2 25 6 73289 75686 
3 3 25 6 72484 82708 
3 1 50 6 79642 76050 
3 2 50 6 71763 82204 
3 3 50 6 77956 81583 
3 1 75 6 70614 80623 
3 2 75 6 74232 77073 
3 3 75 6 72791 78477 
3 1 0 24 120877 95707 
3 2 0 24 133155 95452 
3 3 0 24 140164 102703 
3 1 25 24 132134 93376 











IL-6 units IL-17 units 
3 3 25 24 132389 100278 
3 1 50 24 132655 99094 
3 2 50 24 124470 93254 
3 3 50 24 124412 99754 
3 1 75 24 119594 95718 
3 2 75 24 108410 84124 
3 3 75 24 111928 99572 
3 1 0 48 189454 103613 
3 2 0 48 180654 106669 
3 3 0 48 182345 114190 
3 1 25 48 193465 110565 
3 2 25 48 198745 105382 
3 3 25 48 199564 111679 
3 1 50 48 210576 111398 
3 2 50 48 212543 113667 
3 3 50 48 211745 118393 
3 1 75 48 160745 107522 
3 2 75 48 165634 110704 
3 3 75 48 163756 115098 
3 1 0 72 214131 99154 
3 2 0 72 197028 96281 
3 3 0 72 218847 101417 
3 1 25 72 224986 90482 
3 2 25 72 207551 105468 
3 3 25 72 214514 101398 
3 1 50 72 227648 101767 
3 2 50 72 230730 99244 
3 3 50 72 212381 103221 
3 1 75 72 178218 97576 
3 2 75 72 177417 100699 











IL-6 units IL-17 units 
4 1 0 2 56193 91681 
4 2 0 2 58790 100262 
4 3 0 2 59589 102063 
4 1 25 2 53492 92023 
4 2 25 2 58109 99032 
4 3 25 2 56238 93069 
4 1 50 2 56852 99350 
4 2 50 2 56327 90319 
4 3 50 2 60040 101716 
4 1 75 2 61496 95900 
4 2 75 2 57064 89970 
4 3 75 2 62822 97937 
4 1 0 6 72000 120149 
4 2 0 6 74821 113677 
4 3 0 6 73608 110994 
4 1 25 6 72423 112149 
4 2 25 6 73420 113654 
4 3 25 6 71906 111722 
4 1 50 6 71524 113168 
4 2 50 6 70004 110863 
4 3 50 6 72710 109292 
4 1 75 6 69528 111176 
4 2 75 6 66726 105748 
4 3 75 6 72061 109911 
4 1 0 24 91454 145133 
4 2 0 24 101873 136472 
4 3 0 24 97763 151454 
4 1 25 24 87145 137700 
4 2 25 24 98332 137522 
4 3 25 24 94630 137218 











IL-6 units IL-17 units 
4 2 50 24 89416 131679 
4 3 50 24 85921 146623 
4 1 75 24 96890 146250 
4 2 75 24 101705 138334 
4 3 75 24 94024 142318 
4 1 0 48 153277 232784 
4 2 0 48 150954 213876 
4 3 0 48 160242 231441 
4 1 25 48 149020 210629 
4 2 25 48 153636 244413 
4 3 25 48 192548 272974 
4 1 50 48 161194 243936 
4 2 50 48 178898 253601 
4 3 50 48 188286 268725 
4 1 75 48 189056 267568 
4 2 75 48 183973 261050 
4 3 75 48 191366 263596 
4 1 0 72 224869 201232 
4 2 0 72 223751 198988 
4 3 0 72 241397 201343 
4 1 25 72 229133 200649 
4 2 25 72 234572 224403 
4 3 25 72 240885 212974 
4 1 50 72 223985 223956 
4 2 50 72 210452 233691 
4 3 50 72 223732 230725 
4 1 75 72 206895 217558 
4 2 75 72 223400 211031 





7.15.2  hCO in monoculture 
Viability fluorescent unit data for hCO cultured in monoculture in the presence of 0, 
25, 50 or 75 ng/mL IL-17 or IL-6 at time points 2, 6, 24, 48 or 72 hours. Culture 














1 1 0 2 TS_yes 54269 50773 
1 2 0 2 TS_yes 50807 50138 
1 3 0 2 TS_yes 52362 51408 
1 1 25 2 TS_yes 52249 55840 
1 2 25 2 TS_yes 55482 55025 
1 3 25 2 TS_yes 55263 56231 
1 1 50 2 TS_yes 56505 63253 
1 2 50 2 TS_yes 56384 62353 
1 3 50 2 TS_yes 55374 61342 
1 1 75 2 TS_yes 50153 59720 
1 2 75 2 TS_yes 50772 53565 
1 3 75 2 TS_yes 52362 58745 
1 1 0 6 TS_yes 58072 53663 
1 2 0 6 TS_yes 64253 53612 
1 3 0 6 TS_yes 66907 53145 
1 1 25 6 TS_yes 64907 54283 
1 2 25 6 TS_yes 67081 52347 
1 3 25 6 TS_yes 66908 52527 
1 1 50 6 TS_yes 63103 64430 
1 2 50 6 TS_yes 64270 64908 
1 3 50 6 TS_yes 64719 63452 
1 1 75 6 TS_yes 64325 64188 
1 2 75 6 TS_yes 64173 64354 
1 3 75 6 TS_yes 63053 64243 
1 1 0 24 TS_yes 69348 61915 















1 3 0 24 TS_yes 70352 60974 
1 1 25 24 TS_yes 75693 67724 
1 2 25 24 TS_yes 72098 67942 
1 3 25 24 TS_yes 74362 67321 
1 1 50 24 TS_yes 70418 68255 
1 2 50 24 TS_yes 71110 68639 
1 3 50 24 TS_yes 74785 68575 
1 1 75 24 TS_yes 74128 69112 
1 2 75 24 TS_yes 73918 66225 
1 3 75 24 TS_yes 72362 69534 
1 1 0 48 TS_yes 99990 77609 
1 2 0 48 TS_yes 95440 76910 
1 3 0 48 TS_yes 96988 75282 
1 1 25 48 TS_yes 96199 78772 
1 2 25 48 TS_yes 100386 75775 
1 3 25 48 TS_yes 100232 78545 
1 1 50 48 TS_yes 101922 84447 
1 2 50 48 TS_yes 102252 80123 
1 3 50 48 TS_yes 103353 82325 
1 1 75 48 TS_yes 103228 89656 
1 2 75 48 TS_yes 102624 82019 
1 3 75 48 TS_yes 101306 89564 
1 1 0 72 TS_yes 98235 83672 
1 2 0 72 TS_yes 98415 88442 
1 3 0 72 TS_yes 95463 84200 
1 1 25 72 TS_yes 99994 83579 
1 2 25 72 TS_yes 96564 81273 
1 3 25 72 TS_yes 99362 83254 
1 1 50 72 TS_yes 98706 87527 
1 2 50 72 TS_yes 99374 83724 















1 1 75 72 TS_yes 99856 90354 
1 2 75 72 TS_yes 98889 91462 
1 3 75 72 TS_yes 97635 91159 
2 1 0 2 TS_yes 53263 42356 
2 2 0 2 TS_yes 53913 45400 
2 3 0 2 TS_yes 53258 43700 
2 1 25 2 TS_yes 55296 43745 
2 2 25 2 TS_yes 54673 43224 
2 3 25 2 TS_yes 55983 42265 
2 1 50 2 TS_yes 55463 42019 
2 2 50 2 TS_yes 55273 42025 
2 3 50 2 TS_yes 56354 44578 
2 1 75 2 TS_yes 57879 43288 
2 2 75 2 TS_yes 58253 44023 
2 3 75 2 TS_yes 56989 42637 
2 1 0 6 TS_yes 55193 45848 
2 2 0 6 TS_yes 53263 46517 
2 3 0 6 TS_yes 55283 47364 
2 1 25 6 TS_yes 58261 51479 
2 2 25 6 TS_yes 52256 50582 
2 3 25 6 TS_yes 57454 49972 
2 1 50 6 TS_yes 61800 49548 
2 2 50 6 TS_yes 59464 48394 
2 3 50 6 TS_yes 58364 50354 
2 1 75 6 TS_yes 55762 50820 
2 2 75 6 TS_yes 54834 49899 
2 3 75 6 TS_yes 56382 49062 
2 1 0 24 TS_yes 63771 45226 
2 2 0 24 TS_yes 64038 49332 
2 3 0 24 TS_yes 63827 48372 















2 2 25 24 TS_yes 65602 53351 
2 3 25 24 TS_yes 65836 58374 
2 1 50 24 TS_yes 60463 56124 
2 2 50 24 TS_yes 66211 56579 
2 3 50 24 TS_yes 65243 57463 
2 1 75 24 TS_yes 67442 59518 
2 2 75 24 TS_yes 65362 57182 
2 3 75 24 TS_yes 68362 59205 
2 1 0 48 TS_yes 75912 58511 
2 2 0 48 TS_yes 74362 59214 
2 3 0 48 TS_yes 75342 59253 
2 1 25 48 TS_yes 74183 72831 
2 2 25 48 TS_yes 75813 70463 
2 3 25 48 TS_yes 74263 71253 
2 1 50 48 TS_yes 89736 76957 
2 2 50 48 TS_yes 88328 75643 
2 3 50 48 TS_yes 88352 74635 
2 1 75 48 TS_yes 83956 70465 
2 2 75 48 TS_yes 84536 68463 
2 3 75 48 TS_yes 84352 67463 
2 1 0 72 TS_yes 70155 80404 
2 2 0 72 TS_yes 76382 79363 
2 3 0 72 TS_yes 70362 79373 
2 1 25 72 TS_yes 71917 89449 
2 2 25 72 TS_yes 70261 91052 
2 3 25 72 TS_yes 70249 90464 
2 1 50 72 TS_yes 71522 91463 
2 2 50 72 TS_yes 73182 90647 
2 3 50 72 TS_yes 73726 90536 
2 1 75 72 TS_yes 76378 90287 















2 3 75 72 TS_yes 77352 91647 
3 1 0 2 TS_yes 53267 51473 
3 2 0 2 TS_yes 51834 52438 
3 3 0 2 TS_yes 49362 51407 
3 1 25 2 TS_yes 52349 51980 
3 2 25 2 TS_yes 54472 52235 
3 3 25 2 TS_yes 52264 51132 
3 1 50 2 TS_yes 53567 52453 
3 2 50 2 TS_yes 56399 52923 
3 3 50 2 TS_yes 55382 52232 
3 1 75 2 TS_yes 50253 54720 
3 2 75 2 TS_yes 50932 53665 
3 3 75 2 TS_yes 51352 59745 
3 1 0 6 TS_yes 57083 53663 
3 2 0 6 TS_yes 61236 53612 
3 3 0 6 TS_yes 62998 53145 
3 1 25 6 TS_yes 64912 55283 
3 2 25 6 TS_yes 67232 55347 
3 3 25 6 TS_yes 63271 55527 
3 1 50 6 TS_yes 64124 57430 
3 2 50 6 TS_yes 66254 58908 
3 3 50 6 TS_yes 67700 56452 
3 1 75 6 TS_yes 62323 56188 
3 2 75 6 TS_yes 64352 59354 
3 3 75 6 TS_yes 62349 59993 
3 1 0 24 TS_yes 69348 61911 
3 2 0 24 TS_yes 70623 61484 
3 3 0 24 TS_yes 70352 60974 
3 1 25 24 TS_yes 75693 57724 
3 2 25 24 TS_yes 72098 50942 















3 1 50 24 TS_yes 70418 72255 
3 2 50 24 TS_yes 71110 71639 
3 3 50 24 TS_yes 74785 72575 
3 1 75 24 TS_yes 74128 72112 
3 2 75 24 TS_yes 73918 71225 
3 3 75 24 TS_yes 72344 73884 
3 1 0 48 TS_yes 99990 77610 
3 2 0 48 TS_yes 95440 76912 
3 3 0 48 TS_yes 96988 75287 
3 1 25 48 TS_yes 99199 78772 
3 2 25 48 TS_yes 100386 75775 
3 3 25 48 TS_yes 100232 78545 
3 1 50 48 TS_yes 100266 84447 
3 2 50 48 TS_yes 107754 80123 
3 3 50 48 TS_yes 100563 82325 
3 1 75 48 TS_yes 103228 89656 
3 2 75 48 TS_yes 100624 89019 
3 3 75 48 TS_yes 100706 89854 
3 1 0 72 TS_yes 97235 75672 
3 2 0 72 TS_yes 97275 75442 
3 3 0 72 TS_yes 96976 74200 
3 1 25 72 TS_yes 95344 81979 
3 2 25 72 TS_yes 96694 81113 
3 3 25 72 TS_yes 95852 84654 
3 1 50 72 TS_yes 95922 87197 
3 2 50 72 TS_yes 96252 83664 
3 3 50 72 TS_yes 96353 87761 
3 1 75 72 TS_yes 97656 80454 
3 2 75 72 TS_yes 97189 80362 
3 3 75 72 TS_yes 96235 80459 















1 2 0 2 TS_no 53913 42356 
1 3 0 2 TS_no 53258 45400 
1 1 25 2 TS_no 55296 53700 
1 2 25 2 TS_no 54673 53745 
1 3 25 2 TS_no 55983 53124 
1 1 50 2 TS_no 55463 49265 
1 2 50 2 TS_no 55273 50019 
1 3 50 2 TS_no 56354 52023 
1 1 75 2 TS_no 57879 44577 
1 2 75 2 TS_no 58253 43288 
1 3 75 2 TS_no 56989 44020 
1 1 0 6 TS_no 57044 49655 
1 2 0 6 TS_no 60628 48714 
1 3 0 6 TS_no 60199 49283 
1 1 25 6 TS_no 60783 52131 
1 2 25 6 TS_no 62056 54131 
1 3 25 6 TS_no 63131 53222 
1 1 50 6 TS_no 62040 53476 
1 2 50 6 TS_no 64027 52841 
1 3 50 6 TS_no 64253 53423 
1 1 75 6 TS_no 65373 44113 
1 2 75 6 TS_no 66435 46382 
1 3 75 6 TS_no 64532 48897 
1 1 0 24 TS_no 70190 62248 
1 2 0 24 TS_no 73498 61540 
1 3 0 24 TS_no 72354 63454 
1 1 25 24 TS_no 74451 60749 
1 2 25 24 TS_no 79453 62068 
1 3 25 24 TS_no 75643 62460 
1 1 50 24 TS_no 85841 60627 















1 3 50 24 TS_no 82364 61832 
1 1 75 24 TS_no 68324 63418 
1 2 75 24 TS_no 70362 64834 
1 3 75 24 TS_no 69635 62434 
1 1 0 48 TS_no 104353 73456 
1 2 0 48 TS_no 100053 73475 
1 3 0 48 TS_no 99576 70447 
1 1 25 48 TS_no 106139 73658 
1 2 25 48 TS_no 109954 73503 
1 3 25 48 TS_no 107436 74343 
1 1 50 48 TS_no 118454 75555 
1 2 50 48 TS_no 120242 74248 
1 3 50 48 TS_no 125229 78676 
1 1 75 48 TS_no 117444 77060 
1 2 75 48 TS_no 107262 78795 
1 3 75 48 TS_no 115242 79657 
1 1 0 72 TS_no 97366 74647 
1 2 0 72 TS_no 100339 75768 
1 3 0 72 TS_no 100243 74062 
1 1 25 72 TS_no 99815 83070 
1 2 25 72 TS_no 99756 84409 
1 3 25 72 TS_no 98363 84841 
1 1 50 72 TS_no 100794 78370 
1 2 50 72 TS_no 98457 80453 
1 3 50 72 TS_no 100263 85335 
1 1 75 72 TS_no 93624 79645 
1 2 75 72 TS_no 91550 78195 
1 3 75 72 TS_no 94536 81701 
2 1 0 2 TS_no 42363 44773 
2 2 0 2 TS_no 43253 44138 















2 1 25 2 TS_no 52249 40840 
2 2 25 2 TS_no 55482 42025 
2 3 25 2 TS_no 55263 41232 
2 1 50 2 TS_no 56505 43253 
2 2 50 2 TS_no 56384 42353 
2 3 50 2 TS_no 55374 41342 
2 1 75 2 TS_no 50153 45720 
2 2 75 2 TS_no 50772 43565 
2 3 75 2 TS_no 52362 48745 
2 1 0 6 TS_no 45269 47012 
2 2 0 6 TS_no 46807 46033 
2 3 0 6 TS_no 44362 47022 
2 1 25 6 TS_no 52751 49289 
2 2 25 6 TS_no 54104 47598 
2 3 25 6 TS_no 53254 49756 
2 1 50 6 TS_no 59890 49229 
2 2 50 6 TS_no 57737 49949 
2 3 50 6 TS_no 57976 48785 
2 1 75 6 TS_no 59732 51689 
2 2 75 6 TS_no 58764 55643 
2 3 75 6 TS_no 60352 54273 
2 1 0 24 TS_no 58754 52277 
2 2 0 24 TS_no 58375 51622 
2 3 0 24 TS_no 57352 52432 
2 1 25 24 TS_no 60276 51430 
2 2 25 24 TS_no 59647 52274 
2 3 25 24 TS_no 55278 51362 
2 1 50 24 TS_no 65068 51430 
2 2 50 24 TS_no 63525 53620 
2 3 50 24 TS_no 64736 53264 















2 2 75 24 TS_no 61283 55783 
2 3 75 24 TS_no 61243 56354 
2 1 0 48 TS_no 61905 71933 
2 2 0 48 TS_no 63907 71253 
2 3 0 48 TS_no 60242 71823 
2 1 25 48 TS_no 63182 73315 
2 2 25 48 TS_no 62352 72624 
2 3 25 48 TS_no 64362 77463 
2 1 50 48 TS_no 67700 86743 
2 2 50 48 TS_no 68787 87354 
2 3 50 48 TS_no 68464 86399 
2 1 75 48 TS_no 68633 89159 
2 2 75 48 TS_no 69677 89124 
2 3 75 48 TS_no 67666 88125 
2 1 0 72 TS_no 66511 61301 
2 2 0 72 TS_no 68611 59262 
2 3 0 72 TS_no 67243 58374 
2 1 25 72 TS_no 64407 68195 
2 2 25 72 TS_no 60033 69244 
2 3 25 72 TS_no 62203 68128 
2 1 50 72 TS_no 76387 80362 
2 2 50 72 TS_no 75981 80622 
2 3 50 72 TS_no 76453 82122 
2 1 75 72 TS_no 84977 90383 
2 2 75 72 TS_no 80756 92688 
2 3 75 72 TS_no 80453 90726 
3 1 0 2 TS_no 53234 45363 
3 2 0 2 TS_no 54013 42356 
3 3 0 2 TS_no 53408 45400 
3 1 25 2 TS_no 55296 53700 















3 3 25 2 TS_no 55983 53124 
3 1 50 2 TS_no 55463 49265 
3 2 50 2 TS_no 55273 50019 
3 3 50 2 TS_no 56354 52023 
3 1 75 2 TS_no 57879 44113 
3 2 75 2 TS_no 58253 46382 
3 3 75 2 TS_no 56989 48897 
3 1 0 6 TS_no 57124 49655 
3 2 0 6 TS_no 58928 48714 
3 3 0 6 TS_no 59199 49283 
3 1 25 6 TS_no 60783 52131 
3 2 25 6 TS_no 62056 54131 
3 3 25 6 TS_no 63131 53222 
3 1 50 6 TS_no 62040 53476 
3 2 50 6 TS_no 64027 52841 
3 3 50 6 TS_no 64253 53423 
3 1 75 6 TS_no 65373 54577 
3 2 75 6 TS_no 66435 53288 
3 3 75 6 TS_no 64532 54020 
3 1 0 24 TS_no 71192 58248 
3 2 0 24 TS_no 72497 59540 
3 3 0 24 TS_no 71358 59454 
3 1 25 24 TS_no 74451 60749 
3 2 25 24 TS_no 79453 62068 
3 3 25 24 TS_no 75643 60460 
3 1 50 24 TS_no 85841 60627 
3 2 50 24 TS_no 84326 63995 
3 3 50 24 TS_no 82364 61832 
3 1 75 24 TS_no 68324 60418 
3 2 75 24 TS_no 70362 64834 















3 1 0 48 TS_no 104563 78456 
3 2 0 48 TS_no 102055 77475 
3 3 0 48 TS_no 100576 78447 
3 1 25 48 TS_no 105839 83658 
3 2 25 48 TS_no 109754 83503 
3 3 25 48 TS_no 108766 84343 
3 1 50 48 TS_no 115654 85555 
3 2 50 48 TS_no 115242 80248 
3 3 50 48 TS_no 120229 85676 
3 1 75 48 TS_no 112444 84060 
3 2 75 48 TS_no 113262 86795 
3 3 75 48 TS_no 112242 86657 
3 1 0 72 TS_no 97366 69647 
3 2 0 72 TS_no 100339 75768 
3 3 0 72 TS_no 100243 73062 
3 1 25 72 TS_no 100615 93070 
3 2 25 72 TS_no 100656 97409 
3 3 25 72 TS_no 106783 94841 
3 1 50 72 TS_no 101094 78370 
3 2 50 72 TS_no 108577 80453 
3 3 50 72 TS_no 107264 85335 
3 1 75 72 TS_no 108624 79645 
3 2 75 72 TS_no 107450 78195 










7.15.3 hPDLC in co-culture 
Viability fluorescent unit data for hPDLC cultured in the presence of 75 ng/mL IL-17 
and/or IL-6 at 48 hours in co-culture with hCO cells. Culture media supplemented 
















1 1 0 TS_yes 90588   
1 2 0 TS_yes 84992   
1 3 0 TS_yes 86574   
2 1 0 TS_yes 71292   
2 2 0 TS_yes 77979   
2 3 0 TS_yes 73264   
3 1 0 TS_yes 106792   
3 2 0 TS_yes 105342   
3 3 0 TS_yes 104637   
1 1 75 TS_yes 95647 116365 86244 
1 2 75 TS_yes 94536 113856 85588 
1 3 75 TS_yes 95299 114536 87343 
2 1 75 TS_yes 92843 85101 83155 
2 2 75 TS_yes 92583 87073 81054 
2 3 75 TS_yes 93654 86372 82453 
3 1 75 TS_yes 136476 119612 138596 
3 2 75 TS_yes 139320 125845 144645 
3 3 75 TS_yes 143102 119087 140635 
1 1 0 TS_no 98927   
1 2 0 TS_no 95266   
1 3 0 TS_no 95736   
2 1 0 TS_no 81065   
2 2 0 TS_no 88978   
2 3 0 TS_no 84838   
3 1 0 TS_no 140095   
159 
 
3 2 0 TS_no 140436   
3 3 0 TS_no 139736   
1 1 75 TS_no 118754 120380 119783 
1 2 75 TS_no 115647 119961 123358 
1 3 75 TS_no 116354 118266 120263 
2 1 75 TS_no 100308 106266 135061 
2 2 75 TS_no 104352 99917 125352 
2 3 75 TS_no 106063 105243 128232 
3 1 75 TS_no 155468 156114 167959 
3 2 75 TS_no 149939 149551 158982 





7.15.4. hCO in co-culture 
Viability fluorescent unit data for hCO cultured in the presence of 75 ng/mL IL-17 
and/or IL-6 at 48 hours in co-culture with hPDLC. Culture media supplemented with 















1 1 0 TS_yes 91824   
1 2 0 TS_yes 90564   
1 3 0 TS_yes 91288   
2 1 0 TS_yes 98760   
2 2 0 TS_yes 99415   
2 3 0 TS_yes 98413   
3 1 0 TS_yes 94490   
3 2 0 TS_yes 92354   
3 3 0 TS_yes 91625   
1 1 75 TS_yes 148741 100228 149881 
1 2 75 TS_yes 140333 102352 147833 
1 3 75 TS_yes 145277 100232 145366 
2 1 75 TS_yes 110222 114350 125216 
2 2 75 TS_yes 115000 112878 120232 
2 3 75 TS_yes 111567 112492 119526 
3 1 75 TS_yes 112864 105351 128420 
3 2 75 TS_yes 109152 104263 127223 
3 3 75 TS_yes 110223 100625 128524 
1 1 0 TS_no 71783   
1 2 0 TS_no 72932   
1 3 0 TS_no 71263   
2 1 0 TS_no 92796   
2 2 0 TS_no 93772   
2 3 0 TS_no 93765   
















3 2 0 TS_no 99424   
3 3 0 TS_no 100232   
1 1 75 TS_no 90263 93751 107698 
1 2 75 TS_no 90277 95277 117317 
1 3 75 TS_no 92322 95277 112873 
2 1 75 TS_no 95335 90749 90465 
2 2 75 TS_no 90456 93831 92108 
2 3 75 TS_no 92354 91253 90564 
3 1 75 TS_no 94517 98073 88935 
3 2 75 TS_no 90812 95647 89204 





7.16. qPCR 2^-deltaCq values  
7.16.1.  hPDLC in mono-culture 
2^-deltaCq units forhPDLCs cultured in the presence of 0, 50 or 75 ng/mL IL-6 or IL-












1 0 RANK 7.746E-07 1.3293E-05 
2 0 RANK 1.660E-06 1.4556E-05 
3 0 RANK 8.019E-07 1.441E-06 
4 0 RANK 1.418E-07 1.2707E-05 
1 50 RANK 4.768E-07 1.0422E-05 
2 50 RANK 8.465E-06 1.1341E-06 
3 50 RANK 1.258E-06 1.2831E-05 
4 50 RANK 4.696E-06 5.3948E-06 
1 75 RANK 1.915E-04 2.1579E-05 
2 75 RANK 5.501E-05 1.6354E-05 
3 75 RANK 1.424E-05 1.2394E-05 
4 75 RANK 1.815E-05 2.234E-05 
1 0 RANKL 7.746E-07 7.4876E-07 
2 0 RANKL 5.585E-06 9.5627E-08 
3 0 RANKL 8.019E-07 1.2303E-07 
4 0 RANKL 6.981E-07 5.6158E-07 
1 50 RANKL 9.537E-07 1.7453E-07 
2 50 RANKL 1.719E-06 1.5492E-06 
3 50 RANKL 6.416E-06 6.9813E-07 
4 50 RANKL 1.474E-05 3.3209E-06 
1 75 RANKL 1.983E-04 2.191E-06 
2 75 RANKL 2.441E-04 2.1487E-07 
3 75 RANKL 4.696E-06 8.1422E-08 
4 75 RANKL 3.098E-06 1.8069E-07 













2 0 OPG 0.25 0.18074154 
3 0 OPG 0.25881623 0.36488152 
4 0 OPG 0.42044821 0.5307116 
1 50 OPG 0.19614602 0.18946457 
2 50 OPG 0.1767767 0.14358729 
3 50 OPG 0.2102241 0.21763764 
4 50 OPG 0.42044821 0.61557221 
1 75 OPG 8.5741877 0.2030631 
2 75 OPG 0.70710678 0.14865089 
3 75 OPG 0.28717459 0.08246924 
4 75 OPG 0.65975396 0.48296816 
1 0 ALP 0.0007401 0.0003703 
2 0 ALP 0.0009433 0.0007567 
3 0 ALP 0.00377319 0.00071266 
4 0 ALP 0.00680118 0.00193426 
1 50 ALP 0.00044006 0.00033351 
2 50 ALP 0.00153239 0.0007401 
3 50 ALP 0.00328475 0.00054178 
4 50 ALP 0.00897421 0.00285954 
1 75 ALP 0.02134438 0.00116134 
2 75 ALP 0.01184154 0.00306478 
3 75 ALP 0.00515433 0.00142977 





7.16.2. hCO in monoculture 
2^-deltaCq units for hCOs cultured in the presence of 0, 50 or 75 ng/mL IL-6 or IL-17 












1 0 RANK TS_No 0.00704102 0.0099575 
2 0 RANK TS_No 0.00433426 0.00754638 
3 0 RANK TS_No 0.01509276 0.01104854 
1 50 RANK TS_No 0.00533609 0.01617601 
2 50 RANK TS_No 0.00680118 0.03983002 
3 50 RANK TS_No 0.00754638 0.01617601 
1 75 RANK TS_No 0.00515433 0.05440941 
2 75 RANK TS_No 0.00728932 0.14865089 
3 75 RANK TS_No 0.00808801 0.23325825 
1 0 RANKL TS_No 1.0422E-05 1.5259E-05 
2 0 RANKL TS_No 2.234E-05 8.7639E-06 
3 0 RANKL TS_No 1.6354E-05 1.5797E-05 
1 50 RANKL TS_No 7.6294E-06 1.0067E-05 
2 50 RANKL TS_No 1.6931E-05 2.3944E-05 
3 50 RANKL TS_No 1.5797E-05 1.9448E-05 
1 75 RANKL TS_No 9.2512E-05 6.3188E-05 
2 75 RANKL TS_No 1.7528E-05 3.438E-06 
3 75 RANKL TS_No 8.177E-06 9.9152E-05 
1 0 OPG TS_No 0.51763246 2.54912125 
2 0 OPG TS_No 0.29730178 2.21913894 
3 0 OPG TS_No 0.61557221 0.73204285 
1 50 OPG TS_No 0.45062523 0.35355339 
2 50 OPG TS_No 0.61557221 0.93303299 
3 50 OPG TS_No 0.55478474 1.27456063 
1 75 OPG TS_No 0.4061262 0.48296816 













3 75 OPG TS_No 0.63728031 0.63728031 
1 0 ALP TS_No 0.02627801 0.87055056 
2 0 ALP TS_No 0.01408204 0.45062523 
3 0 ALP TS_No 0.01794841 0.11265631 
1 50 ALP TS_No 0.02816408 0.03235203 
2 50 ALP TS_No 0.03349292 0.07694653 
3 50 ALP TS_No 0.04903651 0.10511205 
1 75 ALP TS_No 0.02209709 0.05076577 
2 75 ALP TS_No 0.03125 0.03349292 
3 75 ALP TS_No 0.07432544 0.04123462 
1 0 RANK TS_yes 0.009958 0.000236 
2 0 RANK TS_yes 0.007546 0.000205 
3 0 RANK TS_yes 0.011049 0.00014 
1 50 RANK TS_yes 0.016176 0.00037 
2 50 RANK TS_yes 0.03983 0.000145 
3 50 RANK TS_yes 0.016176 0.000145 
1 75 RANK TS_yes 0.054409 0.000601 
2 75 RANK TS_yes 0.148651 0.00074 
3 75 RANK TS_yes 0.233258 0.00074 
1 0 RANKL TS_yes 1.53E-05 8.02E-07 
2 0 RANKL TS_yes 8.76E-06 3.61E-07 
3 0 RANKL TS_yes 1.58E-05 7.23E-07 
1 50 RANKL TS_yes 1.01E-05 3.44E-06 
2 50 RANKL TS_yes 2.39E-05 3.21E-06 
3 50 RANKL TS_yes 1.94E-05 3.32E-06 
1 75 RANKL TS_yes 6.32E-05 7.37E-06 
2 75 RANKL TS_yes 3.44E-06 4.7E-06 
3 75 RANKL TS_yes 9.92E-05 6.64E-06 
1 0 OPG TS_yes 2.549121 0.052556 













3 0 OPG TS_yes 0.732043 0.091505 
1 50 OPG TS_yes 0.353553 0.042689 
2 50 OPG TS_yes 0.933033 0.074325 
3 50 OPG TS_yes 1.274561 0.049037 
1 75 OPG TS_yes 0.482968 0.056328 
2 75 OPG TS_yes 0.517632 0.064704 
3 75 OPG TS_yes 0.63728 0.042689 
1 0 ALP TS_yes 0.870551 0.012691 
2 0 ALP TS_yes 0.450625 0.010309 
3 0 ALP TS_yes 0.112656 0.009618 
1 50 ALP TS_yes 0.032352 0.011438 
2 50 ALP TS_yes 0.076947 0.044194 
3 50 ALP TS_yes 0.105112 0.047366 
1 75 ALP TS_yes 0.050766 0.013139 
2 75 ALP TS_yes 0.033493 0.030186 
3 75 ALP TS_yes 0.041235 0.027205 
 
 
7.16.3. hPDLC in co-culture 
2^-deltaCq units for hPDLCs cultured in the presence of 75 ng/mL IL-6 and/or IL-17 
















1 0 RANK TS_No 0.000129   
2 0 RANK TS_No 0.000633   
3 0 RANK TS_No 0.000436   

















2 75 RANK TS_No 0.002624 0.007211 0.014579 
3 75 RANK TS_No 0.001675 0.00472 0.00373 
1 0 RANKL TS_No 3.1E-05   
2 0 RANKL TS_No 2.48E-06   
3 0 RANKL TS_No 1.15E-06   
1 75 RANKL TS_No 1.35E-05 2.48E-06 8.01E-08 
2 75 RANKL TS_No 1.74E-06 1.28E-06 2.07E-06 
3 75 RANKL TS_No 1.67E-06 4.82E-07 8.01E-08 
1 0 OPG TS_No 0.521775   
2 0 OPG TS_No 0.472865   
3 0 OPG TS_No 0.310464   
1 75 OPG TS_No 0.225391 0.148034 0.055456 
2 75 OPG TS_No 0.439367 0.588657 0.249827 
3 75 OPG TS_No 0.168288 0.201521 0.315672 
1 0 ALP TS_No 0.000211   
2 0 ALP TS_No 0.004704   
3 0 ALP TS_No 0.001417   
1 75 ALP TS_No 0.000801 0.000554 0.003328 
2 75 ALP TS_No 0.002143 0.004233 0.00223 
3 75 ALP TS_No 0.00039 0.000526 0.000417 
1 0 RANK TS_yes 4.6E-05   
2 0 RANK TS_yes 0.000699   
3 0 RANK TS_yes 0.000134   
1 75 RANK TS_yes 0.000202 0.000713 0.001798 
2 75 RANK TS_yes 0.005343 0.034043 0.004779 
3 75 RANK TS_yes 0.012931 0.003696 0.001377 
1 0 RANKL TS_yes 0.000493   
2 0 RANKL TS_yes 6.37E-07   

















1 75 RANKL TS_yes 8.83E-05 0.000168 8.16E-05 
2 75 RANKL TS_yes 0.000985 1.49E-05 5.26E-06 
3 75 RANKL TS_yes 0.000178 1.31E-05 2.89E-05 
1 0 OPG TS_yes 0.121456   
2 0 OPG TS_yes 0.418558   
3 0 OPG TS_yes 0.176654   
1 75 OPG TS_yes 0.020496 0.060287 0.039227 
2 75 OPG TS_yes 0.085023 1.379839 0.223911 
3 75 OPG TS_yes 0.321524 0.312407 0.270181 
1 0 ALP TS_yes 0.002415   
2 0 ALP TS_yes 0.009682   
3 0 ALP TS_yes 0.001739   
1 75 ALP TS_yes 8.7E-05 0.000486 0.000336 
2 75 ALP TS_yes 0.006549 0.005872 0.001144 
3 75 ALP TS_yes 0.001987 0.000849 0.000237 
 
 
7.16.4. hCO in co-culture 
2^-deltaCq units for hCOs cultured in the presence of 75 ng/mL IL-6 and/or IL-17 at 










IL-17 +  
IL-6 
units 
1 0 RANK TS_No 9.78E-05   
2 0 RANK TS_No 5.67E-05   
3 0 RANK TS_No 5.87E-05   
1 75 RANK TS_No 8.21E-07 2.1E-05 3.45E-05 











IL-17 +  
IL-6 
units 
3 75 RANK TS_No 9.36E-06 3.37E-05 1.13E-06 
1 0 RANKL TS_No 3.95E-05   
2 0 RANKL TS_No 7.92E-06   
3 0 RANKL TS_No 7.4E-06   
1 75 RANKL TS_No 4.32E-05 8.84E-07 1.83E-05 
2 75 RANKL TS_No 0.000352 0.00012 0.000364 
3 75 RANKL TS_No 8.18E-07 5.83E-07 6.22E-07 
1 0 OPG TS_No 0.02275   
2 0 OPG TS_No 0.284204   
3 0 OPG TS_No 0.001037   
1 75 OPG TS_No 5.03E-05 0.006049 0.001249 
2 75 OPG TS_No 0.001364 0.00344 0.002304 
3 75 OPG TS_No 6.46E-05 0.007982 0.014513 
1 0 ALP TS_No 0.000478   
2 0 ALP TS_No 0.000383   
3 0 ALP TS_No 0.000357   
1 75 ALP TS_No 2.81E-06 0.000252 1.14E-06 
2 75 ALP TS_No 2.62E-06 0.000143 7.02E-07 
3 75 ALP TS_No 2.8E-06 0.000166 1.1E-06 
1 0 RANK TS_yes 9.41E-05   
2 0 RANK TS_yes 1.08E-05   
3 0 RANK TS_yes 1.78E-05   
1 75 RANK TS_yes 5.39E-05 0.000389 4.9E-05 
2 75 RANK TS_yes 6.38E-05 0.00042 7.21E-05 
3 75 RANK TS_yes 0.000127 0.000529 1.71E-05 
1 0 RANKL TS_yes 0.000519   
2 0 RANKL TS_yes 3.43E-05   
3 0 RANKL TS_yes 0.000116   
1 75 RANKL TS_yes 0.005668 0.000521 0.00263 











IL-17 +  
IL-6 
units 
3 75 RANKL TS_yes 0.001045 0.000726 0.001161 
1 0 OPG TS_yes 0.028164   
2 0 OPG TS_yes 0.49039   
3 0 OPG TS_yes 0.23965   
1 75 OPG TS_yes 0.004445 0.029698 0.007968 
2 75 OPG TS_yes 0.002184 0.013907 0.006399 
3 75 OPG TS_yes 0.003089 0.027709 0.006081 
1 0 ALP TS_yes 0.003195   
2 0 ALP TS_yes 0.002992   
3 0 ALP TS_yes 0.00149   
1 75 ALP TS_yes 0.000162 0.000409 0.000195 
2 75 ALP TS_yes 7.94E-05 0.000445 0.000157 
3 75 ALP TS_yes 0.000112 0.000392 0.000149 
 
 
 
